Prof. Dr. med. Hans-Joachim Schmoll · Bibliography according to PubMed with Impact Factor...

Bibliography (PubMed)

Prof. Dr. med. Hans-Joachim Schmoll

N Publications total: 420

Impact Factor (cumulative): 1807,55 Citation-Factor (Hirsch) : 64

No. of Publications per year (1997-2016)

No. of Citations per year (1997-2016)

Bibliography according to PubMed with Impact Factor Prof.Dr.med.habil. Hans-Joachim Schmoll

1. Schwoon DR, Schmoll HJ: (1979) Motivation to participate in cancer screening programmes. SOC SCI MED, 13: 283-6. IF: 2,742, anteiliger IF: 1,371

1979 Summe Bewertung = 1,371 Summe IF = 2,742

2. Schmoll HJ, Niederle N, Achterrath W: (1981) [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)]. KLIN WOCHENSCHR, 59: 1177-88. 7031350 IF: 0,809, anteiliger IF: 0,2697


3. Freise J, Mueller WH, Magerstedt P, Schmoll HJ (1982) Pharmacokinetics of liposome encapsulated cisplatin in rats. ARCH INT PHARMACODYN THER 258: 180-92 IF: 2,103, anteiliger IF: 0,701 4. Schmoll H.(1982) Review of etoposide single-agent activity. Cancer Treat

Rev. Jun;9 Suppl:21-30. IF: 4,7 anteiliger IF: 4,7

5. Schindler E, Waegner W, Schmoll H, Zockler H. . [Role of lymphadenectomy

in stages I and II of non-seminoma tumors. Report of their modern chemotherapy (author's transl)]. J Urol (Paris). 1982;88(5):295-9 IF: 1,91 anteiliger IF: 0,81833


6. Weiss J, von Roemeling R, Peters HD, Schmoll HJ, Diehl V: (1983) [Chemotherapy in pretreated Hodgkin's disease with lomustine, bleomycin, vinblastine and dexamethasone]. Dtsch Med Wochenschr, 108: 1428-32. 6192987 IF: 0,528, anteiliger IF: 0,0587

7. Hacke M, Schmoll HJ, Alt JM, Baumann K, Stolte H (1983) Nephrotoxicity of cisdiamminedichloroplatinum with or without ifosfamide in cancer-treatment. Clin. Physiol. Biochem., 1:17-26. IF: 1,213, anteiliger IF: 0,20217


8. Klose E, Ritter EP, Massopust D, Endert G, Schumann E, Hasse P, Schmoll H, Beyer HK. [Exposure technics for computed scintigrams]. Rofo. 1984 Jul;141(1):97-9.

IF: 1,005 anteiliger IF:0,05584


9. Gabius HJ, Engelhardt R, Casper J, Reile D, Schumacher S, Schmoll HJ,

Graupner G, Cramer F: (1985) Cell surface lectins of transplantable human teratocarcinoma cells: purification of a new mannan-specific endogenous lectin. TUMOR BIOL, 6: 145-56. 4048775 IF: 2,143, anteiliger IF: 0,1906


10. Gabius HJ, Engelhardt R, Casper J, Schmoll HJ, Nagel GA, Cramer F: (1986) Comparison of endogenous lectins in human embryonic carcinoma and yolk sac carcinoma. TUMOR BIOL, 6: 471-82. 3010437 IF: 2,143, anteiliger IF: 0,178584

11. Peest D, Schmoll HJ, Schedel I, Deicher H, Boll J, Essers U, Gamm H, Gluck S, Gorg K, Gramatzki M, et A: (1986) Current results of a multicenter trial in multiple myeloma. Onkologie, 9: 168-9. 3528964 IF: 0,868, anteiliger IF: 0,03617


12. Berdel WE, Berger MR, Falk H, Harstrick A, Danhauser S, Schick HD, Schmoll HJ, Schmahl D, Vogler WR, Rastetter J: (1987) Lack of therapeutic activity of the lipoidal amine CP-46,665 in rodent tumors and human non-seminomatous germ cell tumors growing in nude mice. CANCER LETT, 38: 191-7. 2825966 IF: 4,238, anteiliger IF: 0,17658

13. Casper J, Schmoll HJ, Schnaidt U, Fonatsch C: (1987) Cell lines of human germinal cancer. INT J ANDROL, 10: 105-13. 3034787 IF: 3,519, anteiliger IF: 0,5865

14. Creutzig A, Polking W, Schmoll HJ, Fabel H, Alexander K: (1987) [Raynaud syndrome and changes in lung function as sequelae of cytostatic therapy of testicular tumors]. Med Klin Intensivmed Notfmed, 82: 131-4. 2436030 IF: 0,343, anteiliger IF: 0,0382

15. Gabius HJ, Bokemeyer C, Hellmann T, Schmoll HJ: (1987) Targeting of neoglycoprotein-drug conjugates to cultured human embryonal carcinoma cells. J CANCER RES CLIN, 113: 126-30. 3031079 IF: 2,558 anteiliger IF: 0,8527

16. Harstrick A, Casper J, Schmoll HJ: (1987) Comparative antitumour activity of cisplatin and two new cisplatin-analogues JM8 and JM9 in human testicular carcinoma xenografts. INT J ANDROL, 10: 139-45. 3034790 IF: 3,591, anteiliger IF: 1,197

17. Schmoll HJ, Schubert I, Arnold H, Dolken G, Hecht T, Bergmann L, Illiger J, Fink U, Preiss J, Pfreundschuh M, et A: (1987) Disseminated testicular cancer with bulky disease: results of a phase-II study with cisplatin ultra high dose/VP-16/bleomycin. INT J ANDROL, 10: 311-7. 2438224 IF: 3,591, anteiliger IF: 1,197

18. von Wussow P, Freund M, Block B, Diedrich H, Schmoll H, Poliwoda H, Deicher H. [Low-dose alpha-interferon treatment of hairy cell leukemia]. Klin Wochenschr. 1987 Jul 15;65(14):681-4.

IF: 0,1 anteiliger IF: 0,00666


19. Calavrezos A, Koschel G, Husselmann H, Taylessani A, Heilmann HP, Fabel H, Schmoll HJ, Dietrich H, Hain E: (1988) Malignant mesothelioma of the pleura. A prospective therapeutic study of 132 patients from 1981-1985. KLIN WOCHENSCHR, 66: 607-13. 3210656 IF: 0,809 anteiliger IF: 0,03852

20. Peest D, Schmoll HJ, Schedel I, Gluck S, Schumacher K, Deicher H: (1988) VBAMDex chemotherapy in advanced multiple myeloma. EUR J HAEMATOL, 40: 245-9. 3356240 IF: 2,004, anteiliger IF: 0,167

21. Verbeek W, Bokemeyer C, Falk H, Schmoll HJ: (1988) Growth requirements, growth factor responsiveness, and growth factor secretion of three human embryonal carcinoma cell lines. J CANCER RES CLIN, 114: 553-8. 3204101 IF: 2,558 anteiliger IF: 0,8527

22. Wilke H, Achterrath W, Schmoll HJ, Gunzer U, Preusser P, Lenaz L: (1988) Etoposide and split-dose cisplatin in small-cell lung cancer. AM J CLIN ONCOL-CANC, 11: 572-8. 2845770 IF: 2,002 anteiliger IF: 0,16684

23. Wilke H, Schmoll HJ, Preusser P, Fink U, Stahl M, Schober C, Link H, Freund M, Hanauske A, Meyer HJ, et A: (1988) Folinic acid (CF)/5-fluorouracil (FUra) combinations in advanced gastrointestinal carcinomas. ADV EXP MED BIOL, 244: 233-43. 3073658 IF: 1,093 anteiliger IF: 0,04554

24. Wilke H, Schmoll HJ, Schober C, Stahl M, Preusser P, Freund M, Poliwoda H: (1988) Folinic acid (FA) plus 5-fluorouracil (FU) in progressive advanced colorectal cancer. BIOMED PHARMACOTHER, 42: 373-80. 3064821 IF: 2 anteiliger IF: 0,14

25. Peest D, Deicher H, Coldewey R, Schmoll HJ, Schedel I (1988) Induction and maintenance-therapy in multiple myeloma: A multicenter trial of MP vs. VCMP. EUR J CANCER CLIN ONCOL, 24:1061-7 IF: 5,536 anteiliger IF: 0,6152


26. Arnemann J, Gradl G, Casper J, Schmoll HJ, Schmidtke J, Fonatsch C: (1989) Characterization of rearranged Y chromosomes in human testicular tumor cell lines. CANCER GENET CYTOGEN, 37: 141-51. 2539248 IF: 1,389, anteiliger IF: 0,11575

27. Bokemeyer B, Grote R, Schmoll E, Freise J, Schmoll HJ, Galanski M, Schuler A, Schmidt FW: (1989) [Chemoembolization of hepatocellular carcinoma with lipiodol, epirubicin and cisplatin]. Dtsch Med Wochenschr, 114: 128-32. 2536606 IF: 0,528 anteiliger IF: 0,0294

28. Harstrick A, Casper J, Guba R, Wilke H, Poliwoda H, Schmoll HJ: (1989) Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vivo and in vitro. CANCER-AM CANCER SOC, 63: 1079-83. 2645036 IF: 4,771 anteiliger IF: 1,5904

29. Schmoll HJ: (1989) The role of ifosfamide in testicular cancer. SEMIN ONCOL, 16(1 Suppl 3): 82-95. 2649987


30. Winkler K, Torggler S, Beron G, Bode U, Gerein V, Jurgens H, Kusnierz-Glaz C, Kotz R, Salzer-Kuntschik M, Schmoll HJ, et A: (1989) [Results of treatment in primary disseminated osteosarcoma. Analysis of the follow-up of patients in the cooperative osteosarcoma studies COSS-80 and COSS-82]. Onkologie, 12: 92-6. 2660050 IF: 0,173 anteiliger IF: 0,0577

26. Meyer HJ, Jahne J, Pichlmayr R, Wilke H, Schmoll HJ, Poliwoda H (1989) Interdisciplinary therapy concepts in gastrointestinal tumors: Stomach. Z Gastroenterol Verh, 24:60-5.

IF: 0.067 anteiliger IF: 0,00558

27. Schmoll HJ, (1989) The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes. EUR J CANCER CLON ONCOL, 25:35-9.



28. Harstrick A, Casper J, Kohne-Wompner H, Wilke H, Schmoll HJ, Poliwoda H: (1990) Comparative activity of four anthracyclines against heterotransplanted germ cell tumor lines. INVEST NEW DRUG, 8: S19-24. 1696245 IF: 3,357 anteiliger IF: 0,27975

29. Harstrick A, Schmoll HJ, Casper J, Wilke H, Poliwoda H: (1990) Activity of cytostatic drugs in two heterotransplanted human testicular cancer cell lines with different sensitivity to standard agents. EUR J CANCER, 26: 898-901. 2145935 IF: 5,536 anteiliger IF: 0,6152

30. Harstrick A, Schmoll HJ, Wilke H, Schober C, Stahl M, Wompner CK, Bokemeyer C, Dolken G, Burk K, Poliwoda H: (1990) High dose epirubicin in refractory or relapsed non-seminomatous testicular cancer: a phase II study. ANN ONCOL, 1: 375-6. 2261377 IF: 3, anteiliger IF: 0,125

31. Jackle-Meyer I, Gwinner W, Baum M, Soose M, Petzoldt R, Schmoll HJ, Stolte H: (1990) Significance of Tamm-Horsfall protein excretion in diabetes mellitus and cisplatin nephrotoxicity. CONTRIB NEPHROL, 83: 124-9. 2100702 IF: 1,487 anteiliger IF: 0,09914

32. Preusser P, Wilke H, Achterrath W, Lenaz L, Stahl M, Casper J, Meyer HJ, Meyer J, Blum M, Schmoll HJ: (1990) Phase II study of carboplatin in untreated inoperable advanced stomach cancer. EUR J CANCER, 26: 1108-9. 2148891


33. Schmoll HJ: (1990) Progress in treatment of testicular cancer. J CANCER RES CLIN, 116: 112-5. 2312601 IF: 2,558 anteiliger IF: 2,558

34. Schmoll HJ, Harstrick A, Kohne-Wompner CH, Schober C, Wilke H, Poliwoda H: (1990) Modulation of cytotoxic drug activity by dipyridamole. Cancer Treat Rev, 17: 57-65. 2092872 IF: 6,054 anteiliger IF: 2,018

35. Tesch H, Furbass R, Casper J, Lyons J, Bartram CR, Schmoll HJ, Bronson DL: (1990) Cellular oncogenes in human teratocarcinoma cell lines. INT J ANDROL, 13: 377-88. 2283183 IF: 3,591 anteiliger IF: 0,2394


36. Harstrick A, Schmoll HJ, Bokemeyer C, Metzner B, Illiger HJ, Berdel W, Ostermann H, Manegold C, Rath U, Siegert W, et A: (1991) Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinoma. J CANCER RES CLIN, 117: S198-202. 1665492 IF: 2,558 anteiliger IF: 0,10658

37. Harstrick A, Schmoll HJ, Kohne-Wompner CH, Bergmann L, Lammers U, Hohnloser J, Dolken G, Reichhardt P, Siegert W, Natt F, et A: (1991) Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma. ANN ONCOL, 2: 197-202. 1710481 IF: 4,425 anteiliger IF: 0,18438

38. Harstrick A, Schmoll HJ, Wilke H, Kohne-Wompner CH, Stahl M, Schober C, Casper J, Bruderek L, Schmoll E, Bokemeyer C, et A: (1991) Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J CLIN ONCOL, 9: 1549-55. 1651992 IF: 1,41, anteiliger IF: 0,05875

39. Schmoll E, Wilke H, Thole R, Preusser P, Wildfang I, Schmoll HJ: (1991) Megestrol acetate in cancer cachexia. SEMIN ONCOL, 18(1 Suppl 2): 32-4. 1992534 IF: 3,5 anteiliger IF: 1,17

40. Schmoll HJ: (1991) How should we treat disseminated seminoma? ANN ONCOL, 2: 623-4. 1742217 IF: 1,917 anteiliger IF: 1,917

41. Schmoll HJ: (1991) Introduction: the clinical challenge. EUR J CANCER, 27: S1-2. 1831627 IF: 5,536 anteiliger IF: 5,536

42. Schuppert F, Scheumann GFW, Schöber C, Overbeck J, Schürmeyer T, Schmoll HJ, Dralle H, von zur Mühlen A: (1991) Therapie eines malignen sympathischen Paraganglioms des Zuckerkandlschen Organs - ein Fallbericht. KLIN WOCHENSCHR, 69: 937 - 942 IF: 0,809 anteiliger IF: 0,05394

43. Wilke H, Preusser P, Stahl M, Harstrick A, Meyer HJ, Achterrath W, Schmoll HJ, Seeber S: (1991) Etoposide, folinic acid, and 5-fluorouracil in carboplatin-pretreated patients with advanced gastric cancer. CANCER CHEMOTH PHARM, 29: 83-4. 1742854 IF: 2,833 anteiliger IF: 0,15739

44. Wilke H, Preusser P, Fink U, Meyer HJ, Schmoll HJ, Stahl M, Seeber S, (1991) Modern therapeutic strategies in stomach cancer. Z GASTROENTEROL VERH, 26:217-8 IF:0,896, anteiliger IF: 0,05974


45. Bokemeyer C, Freund M, Schmoll HJ, Rieder H, Fonatsch C: (1992) Secondary lymphoblastic leukemia following treatment of a malignant germ cell tumour. ANN ONCOL, 3: 772. 1280461 IF: 6,425 anteiliger IF: 0,7139

46. Bokemeyer C, Harstrick A, Schmoll HJ, Kohne-Wompner CH, Schoffski P, Poliwoda H: (1992) Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas. ANN ONCOL, 3: 487-8. 1498067 IF: 6,425 anteiliger IF: 0,3542

47. Bokemeyer C, Harstrick A, Schoffski P, Schmoll HJ, Poliwoda H: (1992) [Germ-cell tumors of the testis. The epidemiological and etiological aspects]. Dtsch Med Wochenschr, 117: 1532-7. 1327710 IF: 0,528 anteiliger IF: 0,0587

48. Galanski M, Schmoll E, Reichelt S, Bohmer G, Prokop M, Schaefer C, Schuler A, Ringe B, Schmidt FW, Schmoll HJ: (1992) [Chemoembolization of hepatocellular carcinoma in cases of isolated liver involvement]. RADIOLOGE, 32: 49-55. 1314400 IF: 0,611 anteiliger IF: 0,2037

49. Harstrick A, Bokemeyer C, Preusser P, Kohne-Wompner CH, Meyer HJ, Stahl M, Knipp H, Schmoll HJ, Wilke H: (1992) Phase II study of single-agent

etoposide in patients with metastatic squamous-cell carcinoma of the esophagus. CANCER CHEMOTH PHARM, 29: 321-2. 1537080 IF: 3,5 anteiliger IF: 0,16666

50. Kohne-Wompner CH, Schmoll HJ, Harstrick A, Rustum YM: (1992) Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. SEMIN ONCOL, 19(2 Suppl 3): 105-25. 1373004 IF: 3,5 anteiliger IF: 0,584

51. Schmoll HJ, Bokemeyer C, Harstrick A, Illiger HJ, Metzner B, Ruther U, Osternamm A, Preiss J, Wilke H, Hohnloser J, et A: (1992) Dose escalation of cisplatin (P), etoposide (E), and ifosfamide (I) with GM-CSF for advanced germ cell tumors. PATHOL BIOL, 39: 961. 1538953 IF: 1,528 anteiliger IF: 0,5094

52. Schmoll HJ, Hiddemann W, Rustum Y, Kohne-Wompner CH: (1992) The emerging role for biomodulation of antineoplastic agents. SEMIN ONCOL, 19(2 Suppl 3): 1-3. 1557636 IF: 2,194 anteiliger IF: 0,7314

53. Schmoll HJ, Kohne-Wompner CH, Hiddemann W, Knipp H, Wilke H, Bodenstein H, Schoffski P, Bokemeyer C, Lohrmann HP, Preiss J, et A: (1992) Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial. SEMIN ONCOL, 19(2 Suppl 3): 191-6. 1557646 IF: 2,194 anteiliger IF: 0.7314

54. Schober C, Bokemeyer C, Stahl M, Wilke HJ, Schmoll HJ, Poliwoda H: (1992) The role of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced colorectal cancer. SEMIN ONCOL, 19(2 Suppl 3): 131-5. 1557638 IF: 2,194 anteiliger IF: 0,18284

55. Schober C, Kohne-Wompner CH, Schmoll HJ, Stahl M, Wilke HJ, Poliwoda H: (1992) A 3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal cancer and its impact in terms of palliation. SEMIN ONCOL, 19(2 Suppl 3): 136-40. 1557639 IF: 2,194 anteiliger IF: 0,18284

56. Schober C, Schmoll E, Schmoll HJ, Poliwoda H, Schuppert F, Stahl M, Bokemeyer C, Wilke H, Weiss J: (1992) Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours. EUR J CANCER, 28: 1664-6. 1382494 IF: 2,191 anteiliger IF: 0,1044

57. Stahl M, Wilke HJ, Seeber S, Schmoll HJ: (1992) Cytokines and cytotoxic agents in renal cell carcinoma: a review. SEMIN ONCOL, 19(2 Suppl 4): 70-9. 1553577 IF: 2,194 anteiliger IF: 0,7314

58. Stahl M, Wilke H, Schmoll HJ, Schober C, Diedrich H, Casper J, Freund M, Poliwoda H: (1992) A phase II study of high dose tamoxifen in progressive, metastatic renal cell carcinoma. ANN ONCOL, 3: 167-8. 1606089


59. Wilke H, Stahl M, Schmoll HJ, Preusser P, Fink U, Meyer HJ, Achterrath W, Knipp H, Kohne-Wompner CH, Harstrick A, et A: (1992) Biochemical modulation of 5-fluorouracil by folinic acid or alpha-interferon with and without other cytostatic drugs in gastric, esophageal, and pancreatic cancer. SEMIN ONCOL, 19(2 Suppl 3): 215-9. 1557651 IF: 2,194 anteiliger IF: 0,09142


60. Bokemeyer C, Kuczyk M, Schoffski P, Schmoll HJ: (1993) Familial occurrence of Leydig cell tumors: a report of a case in a father and his adult son. J UROLOGY, 150(5 Pt 1): 1509-10. 8411441 IF: 0,105 anteiliger IF: 0,035

61. Bokemeyer C, Luer M, Schmoll HJ, Freund M, Poliwoda H: (1993) Secondary cancer following Hodgkin's disease. ANN ONCOL, 4: 520-1. 8353097 IF: 1,917 anteiliger IF: 0,213

62. Bokemeyer C, Schmoll HJ: (1993) Secondary neoplasms following treatment of malignant germ cell tumors. J CLIN ONCOL, 11: 1703-9. 8394879 IF: 0,561 anteiliger IF: 0,2805

63. Bokemeyer C, Schmoll HJ: (1993) Treatment of advanced germ cell tumours by dose intensified chemotherapy with haematopoietic growth factors or peripheral blood stem cells (PBSC). Eur Urol, 23: 223-9; discussion 230. 8097467 IF: 8,493 anteiliger IF: 4,265

64. Bokemeyer C, Schmoll HJ: (1993) Treatment strategies in metastatic testicular cancer. Eur Urol, 23: 50-2. 8390363 IF: 1,959 anteiliger IF: 0,9795

65. Bokemeyer C, Schmoll HJ, Harstrick A: (1993) Side-effects of GM-CSF treatment in advanced testicular cancer. EUR J CANCER, 29: 924. 8484987 IF: 1,959 anteiliger IF: 0,653

66. Bokemeyer C, Schmoll HJ, Harstrick A, Illiger HJ, Metzner B, Rath U, Hohnloser J, Clemm C, Berdel W, Siegert W, et A: (1993) A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours. EUR J CANCER, 29: 2225-31. 8110490 IF: 1,41, anteiliger IF: 0,05875

67. Bokemeyer C, Schmoll HJ, Metzner B, Beyer J, Illiger HJ, Kneba M, Ostermann H, Kynast B, Rath U, Poliwoda H: (1993) Comparison of 5 vs 10 micrograms/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular

cancer. ANN HEMATOL, 67: 75-9. 8347733 IF: 1,959, anteiliger IF: 0,08163

68. Bokemeyer C, Schmoll HJ, Schoffski P, Harstrick A, Bading M, Poliwoda H: (1993) Bilateral testicular tumours: prevalence and clinical implications. EUR J CANCER, 29: 874-6. 8387319 IF: 1,959 anteiliger IF: 0,16325

69. Erlichman C, Fine S, Kerr I, Hoffman W, Gorg C, Schmoll HJ, Preusser P, Senn HJ, Gustavsson B: (1993) Experience with 5FU + L-leucovorin. ADV EXP MED BIOL, 339: 77-9; discussion 97-8. 8178731 IF: 0,561 anteiliger IF: 0,02671

70. Grigor KM, Schmoll HJ: (1993) How should we identify high risk testicular tumour patients? Round table discussion. Eur Urol, 23: 207-12. 8386651 IF: 1,307 anteiliger IF: 0,6535

71. Grigor KM, Schmoll HJ: (1993) Should high dose chemotherapy with, or without, autologous bone marrow transplant be included in the primary treatment of testicular cancer? Round table discussion. Eur Urol, 23: 240-4. 8386655 IF: 0,561 anteiliger IF: 0,2805

72. Grundner-Culemann E, Bokemeyer C, Neubauer V, Shalitin C, Schmoll HJ, Poliwoda H, Benter T: (1993) Analysis of a non-ras 21-kDa protein in patients with metastatic testicular germ-cell tumors. J CANCER RES CLIN, 119: 685-8. 8394368 IF: 1,041 anteiliger IF: 0,0694

73. Harstrick A, Bokemeyer C, Scharnofkse M, Hapke G, Reile D, Schmoll HJ: (1993) Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines. CANCER CHEMOTH PHARM, 33: 43-7. 8269588 IF: 1,041 anteiliger IF: 0,347

74. Harstrick A, Bokemeyer C, Schmoll HJ, Kohne-Wompner CH, Knipp H, Schoffski P, Anagnou J, Wipperman B, Neumann S, Poliwoda H: (1993) A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adults. CANCER CHEMOTH PHARM, 31: S217-21. 8453702 IF: 2,833 anteiliger IF: 0,11804

75. Harstrick A, Schmoll HJ, Sass G, Poliwoda H, Rustum Y: (1993) Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines. EUR J CANCER, 29: 1000-2. 8499130 IF: 1,959 anteiliger IF: 0,2177

76. Kohne-Wompner CH, Schmoll HJ: (1993) 5-Fluorouracil modulation in colorectal carcinoma experience of German investigators. ADV EXP MED BIOL, 339: 99-107. 8178734 IF: 1, anteiliger IF: 0,5

77. Kynast B, Binder L, Marx D, Zoll B, Schmoll HJ, Oellerich M, Schauer A: (1993) Determination of a fragment of the c-erbB-2 translational product p185 in serum of breast cancer patients. J CANCER RES CLIN, 119: 249-52. 8095050 IF: 1,307 anteiliger IF: 0,08714

78. Schmoll HJ, Harstrick A, Bokemeyer C, Dieckmann KP, Clemm C, Berdel WE, Souchon R, Schober C, Wilke H, Poliwoda H: (1993) Single-agent carboplatinum for advanced seminoma. A phase II study. CANCER-AM CANCER SOC, 72: 237-43. 8508413 IF: 2,429 anteiliger IF: 0,8096

79. Schmoll HJ, Seeber S: (1993) [Current developments in chemotherapy of advanced testicular tumors]. Urologe A, 32: 207-16. 8511834 IF: 0,36 anteiliger IF: 0,18

80. Schmoll HJ (1993) Management of eary stages of testicular carcinoma: the current status. RECENT RESULTS CANCER RES, 126:237-55 IF: 0,952, anteiliger IF: 0,952

81. Bokemeyer C, Schmoll H, Harstrick A, Kohnewompner H, Poliwoda H. Treatment of adult osteosarcoma - single-center results in 47 patients. Int J Oncol. 1993 Nov;3(5):927-32.


82. Bokemeyer C1, Schmoll H, Casper J, Kuczyk M, Poliwoda H. No growth-stimulation of heterotransplanted human testicular cancer cell-lines by recombinant human granulocyte-macrophage colony-stimulating factor (gm-csf). Int J Oncol. 1993 Jul;3(1):77-80.


83. Bokemeyer C1, Frank B, Schoffski P, Poliwoda H, Schmoll H. Phantom sensations after orchiectomy for testicular cancer. Int J Oncol. 1993 Apr;2(4):633-6.


84. Bokemeyer C1, Harstrick A, Gonnermann O, Schober C, Kuczyk M, Poliwoda H, Schmoll H. Metastatic leydig-cell tumors of the testis - report of 4 cases and review of the literature. Int J Oncol. 1993 Feb;2(2):241-4.

IF: 1,181 anteiliger IF : 0,39366


85. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W: (1994) Treatment intensification in disseminated germ-cell tumors. World J Urol, 12: 207-13. 7820143 IF: 0,561, anteiliger IF: 0,09352

86. Bokemeyer C, Dunn T, Harstrick A, Lerch T, Poliwoda H, Schmoll HJ: (1994) Modulation of cytostatic drugs by nifedipine in two heterotransplanted human testicular-cancer cell lines differing in their sensitivity to standard agents. Int J Cancer, 56: 452-6. 7906255 IF: 3,276, anteiliger IF: 1,09189

87. Bokemeyer C, Harstrick A, Ruther U, Metzner B, Illiger HJ, Clemm C, Siegert W, Link H, Ostermann H, Schmoll HJ: (1994) The role of granulocyte-macrophage colony-stimulating factor in the treatment of germ cell tumors. German Testicular Cancer Study Group. SEMIN ONCOL, 21(6 Suppl 16): 57-63. 7801148 IF: 2,628, anteiliger IF: 0,87591

88. Bokemeyer C, Harstrick A, Schmoll HJ: (1994) The use of carboplatin in malignant germ cell tumours. EUR J CANCER, 30: 721-2. 8080698 IF: 0,789, anteiliger IF: 0,26297

89. Bokemeyer C, Schmoll HJ, Ludwig E, Harstrick A, Dunn T, Casper J: (1994) The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna. BRIT J CANCER, 69: 863-7. 8180015 IF: 3,188, anteiliger IF: 0,26572

90. Bokemeyer C, Schmoll HJ, Natt F, Knoche M, Beyer J, Souchon R: (1994) Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. J CANCER RES CLIN, 120: 754-7. 7798304 IF: 1,654, anteiliger IF: 0,13786

91. Bokemeyer C, Schmoll HJ, Poliwoda H: (1994) [Secondary leukemias after etoposide chemotherapy]. Dtsch Med Wochenschr, 119: 707-13. 8187625 IF: 0,605, anteiliger IF: 0,20171

92. Bokemeyer C, Schmoll HJ, van Rhee J, Kuczyk M, Schuppert F, Poliwoda H: (1994) Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. ANN HEMATOL, 68: 105-10. 8167175 IF: 1,496, anteiliger IF: 0,12469

93. Derigs HG, Huber C, Schmoll HJ: (1994) [Stage-oriented therapy in nonseminomatous testicular tumors]. Dtsch Med Wochenschr, 119: 156-64. 8313845 IF: 0,605, anteiliger IF: 0,20165

94. Hill BT, Shellard SA, Fichtinger-Schepman AM, Schmoll HJ, Harstrick A: (1994) Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines. ANTI-CANCER DRUG, 5: 321-8. 7919457 IF: 1,258, anteiliger IF: 0,13981

95. Kohne-Wompner CH, Schoffski P, Schmoll HJ: (1994) Adjuvant therapy for colon adenocarcinoma: current status of clinical investigation. ANN ONCOL, 5: 97-104. 8204538 IF: 1,914, anteiliger IF: 0,63794

96. Link H, Herrmann F, Welte K, Aulitzky WE, Ganser A, Kern WV, Meyer P, Schrappe M, Schmoll HJ, Werdan K, et A: (1994) [Rational therapy with G-CSF and GM-CSF]. Med Klin Intensivmed Notfmed, 89: 429-41. 7526144 IF: 0,5 anteiliger IF: 0,02084

97. Schmoll HJ: (1994) [Adjuvant chemotherapy in rectal cancer]. CHIRURG, 65: 576-84. 7924595 IF: 0,657, anteiliger IF: 0,657

98. Schmoll HJ: (1994) Colorectal carcinoma: current problems and future perspectives. ANN ONCOL, 5: 115-21. 8204526 IF: 1,914, anteiliger IF: 1,914

99. Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, Zimmermann R, Bokemeyer C, Schmoll HJ, Huhn D: (1994) High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J CLIN ONCOL, 12: 1223-31. 7911158 IF: 7,507, anteiliger IF: 0,31285

100. Casper J1, Casper S, Kohnewompner C, Bokemeyer C, Hecker H, Schmoll H. 5-ht3 antagonist ondansetron for the treatment of chemotherapy-induced nausea and vomiting in an outpatient population. Int J Oncol. 1994 Jun;4(6):1283-9.

IF:1,181 anteiliger IF: 0,3937


101. Bajorin DF, Nichols CR, Schmoll HJ, Kantoff PW, Bokemeyer C, Demetri GD, Einhorn LH, Bosl GJ: (1995) Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. J CLIN ONCOL, 13: 79-86. 7799046 IF: 6,922, anteiliger IF: 0,38463

102. Berger CC, Bokemeyer C, Schneider M, Kuczyk MA, Schmoll HJ: (1995) Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. EUR J CANCER, 31: 2229-38. 8652248 IF: 2,095, anteiliger IF: 0,69826

103. Bokemeyer C, Kynast B, Harstrick A, Laage E, Schmoll E, von Wussow P, Schmoll HJ: (1995) No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma. CANCER CHEMOTH PHARM, 35: 334-8. 7828277 IF: 1,598, anteiliger IF: 0,53261

104. Bokemeyer C, Ludwig E, Reile D, Harstrick A, Poliwoda H, Schmoll HJ: (1995) Antitumour activity and toxicity of continuous infusion versus bolus administration of bleomycin in two heterotransplanted human testicular cancer cell lines. Oncol Rep, 2: 161-165 IF: 0,421, anteiliger IF: 0,14032

105. Bokemeyer C, Schmoll HJ: (1995) Treatment of testicular cancer and the development of secondary malignancies. J CLIN ONCOL, 13: 283-92. 7799032 IF: 6,922, anteiliger IF: 3,461

106. Bokemeyer C, Schmoll HJ: (1995) Sekundärneoplasien nach der Therapie maligner Keimzelltumoren des Hodens. Strahlenther Onkol, 6: 356-357 IF: 2,5 anteiliger IF: 1,25

107. Bokemeyer C, Schmoll HJ, Kuczyk MA, Beyer J, Siegert W: (1995) Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. JNCI-J NATL CANCER I, 87: 58-60. 7666466 IF: 10,165, anteiliger IF: 1,12967

108. Köhne CH, Hiddemann W, Schüller J, Weiss J, Lorhmann HP, Schmitz-Hübner U, Bodenstein H, Schöber C, Wilke H, Grem J, Schmoll HJ: (1995) Failure of orally administered Dipyridamole to enhance the antineoplastic activity for Fluorouracil in combination with Leucovorin in patients with advanced colorectal cancer: a prospective randomized trial. J CLIN ONCOL, 13: 1201-1208 IF: 6,922, anteiliger IF: 2,3071

109. Köhne CH, Schmoll HJ: (1995) Therapiestudien zur adjuvanten und palliativen Therapie. ONKOLOGE, 1: 57-60 IF: 0,173 anteiliger IF: 0,0865

110. Köhne CH, Schmoll HJ, Wilke H, Käufer C, Rauschecker H, Andreesen R, Ohl U, Lange HJ, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Bade J, Strohmeyer G, Schöffski P, Schubert U, Hecker H: (1995) Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer: First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). ANN ONCOL, 6: 461-466 IF: 2,256, anteiliger IF: 0,05014

111. Kuczyk MA, Bokemeyer C, Fichna B, Truss M, Schmoll HJ, Jonas U: (1995) [Differentiated teratoma as late recurrence of metastatic non-seminomatous testicular germ cell tumor. Case report and clinical problems]. Urologe A, 34: 480-4. 8848861 IF: 0,381, anteiliger IF: 0,03176

112. Kuczyk MA, Bokemeyer C, Schmoll HJ, Jonas U: (1995) The prognostic role of alterations of the p53 tumor suppressor gene in superficial and advanced stage bladder cancer. Onkologie, 18: 202-210 IF: 0,462, anteiliger IF: 0,07702

113. Rhomberg W, Schmoll HJ, Schneider B: (1995) High frequency of metalworkers among patients with seminomatous tumors of the testis: a case-control study. AM J IND MED, 28: 79-87. 7573077 IF: 0,987, anteiliger IF: 0,32907

114. Thiel I, Schmoll HJ, Bokemeyer C: (1995) Primary osteogenic sarcoma of the breast: Report of a case and a short review of the literature. Onkologie, 18: 357-361 IF: 0,462, anteiliger IF: 0,15403

115. Bokemeyer C1, Kuczyk M, Fichna B, Jonas U, Poliwoda H, Schmoll H. Late relapse of testicular cancer presenting as differentiated teratoma - report of a case and discussion of the clinical implications. Oncol Rep. 1995 Jul;2(4):615-8.

IF:0,407 anteiliger IF:0,13567


116. Andrews PW, Casper J, Damjanov I, Duggan-Keen M, Giwercman A, Hata JI, von Keitz A, Looijenga LHJ, Millan JL, Oosterhuis JW, Pera M, Sawada M, Schmoll HJ, Skakkebaek NE, van Putten W, Stern P: (1996) Comparative analysis of cell surface antigens expressed by cell lines derived from human germ cell tumors. Int J Cancer, 66: 806-816 IF: 3,534, anteiliger IF: 0,08416

117. Berger C, Bokemeyer C, Schuppert F, Schmoll HJ: (1996) Endocrinological late effects after chemotherapy for testicular cancer. BRIT J CANCER, 73: 1108-1114 IF: 3,666, anteiliger IF: 1,22188

118. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W: (1996) Hochdosischemotherapie bei Hodentumoren. ONKOLOGE, 2: 28-32 IF: 0,173 anteiliger IF: 0,02884

119. Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn LH, Siegert W: (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J CLIN ONCOL, 14: 2638-2645 IF: 7,881, anteiliger IF: 0,26275

120. Beyer J, Kramer A, Mandanas R, Linkesch W, Greinix A, Droz JP, Culine S, Diehl A, Bokemeyer C, Schmoll HJ, Einhorn LH, Nichols CR, Siegert W: (1996) Treatment outcome of high-dose chemotherapy as salvage treatment in male germ cell tumors: a multivariate analysis of prognostic factors. J CLIN ONCOL, 14: 2638-2645 IF: 7,881, anteiliger IF: 0,23887

121. Bokemeyer C, Beyer J, Metzner B, Rüther U, Weißbach L, Köhrmann U, Verbeek W, Harstrick A, Schmoll HJ: (1996) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory cancer. ANN ONCOL, 7: 31-34 IF: 2,736, anteiliger IF: 0,91191

122. Bokemeyer C, Fels LM, Dunn TA, Voigt W, Gaedeke J, Schmoll HJ, Stolte H: (1996) Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide antitumor activity. BRIT J CANCER, 74: 2036-2041 IF: 3,666, anteiliger IF: 0,24445

123. Bokemeyer C, Köhrmann O, Tischler J, Weißbach L, Räth U, Haupt A, Schöffski P, Schmoll HJ: (1996) A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with good risk metastatic non-seminomatous germ cell tumors. ANN ONCOL, 7: 1015-1022 IF: 2,736, anteiliger IF: 0,91191

124. Bokemeyer C, Kuczyk MA, Dunn TA, Serth T, Hartmann K, Jonasson J, Jonas U, Schmoll HJ: (1996) Expression of stem cell factor and its receptor c-kit protein in normal testicular tissue and malignant germ-cell tumors. J CANCER RES CLIN, 122: 301-306 IF: 1,093, anteiliger IF: 0,3643

125. Bokemeyer C, Kuczyk MA, Köhne CH, Einsele H, Kynast B, Schmoll HJ: (1996) Hematopoetic growths factors and treatment of testicular cancer: Biological interactions routine use and dose-intensive chemotherapy. ANN HEMATOL, 72: 1-9 IF: 1,206, anteiliger IF: 0,40196

126. Bokemeyer C, Kuczyk MA, Köhne H, Einsele H, Kynast B, Schmoll HJ: (1996) Treatment of testicular cancer and hematopoietic growth factors: Biological interactions routine use and dose-intensive chemotherapy. ANN HEMATOL, 7: 1-9 IF: 1,206, anteiliger IF: 0,40196

127. Bokemeyer C, Kuczyk MA, Köhne H, Haupt A, Schmoll HJ: (1996) Das Risiko sekundärer Neoplasien nach Behandlung maligner Keimzelltumoren des Hodens. Med Klin Intensivmed Notfmed, 91: 703-710 IF: 0,468 anteiliger IF: 0,156

128. Bokemeyer C, Kuczyk MA, Serth, Hartmann JT, Schmoll HJ, Jonas U, Kanz L: (1996) Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters. J CANCER RES CLIN, 122: 575-584 IF: 1,093, anteiliger IF: 0,07288

129. Bokemyer C, Berger C, Kuczyk MA, Schmoll HJ: (1996) Evaluation of long-term toxicity after chemotherapy for testicular cancer. J CLIN ONCOL, 14: 2923-2932 IF: 7,881, anteiliger IF: 2,62674

130. Borchard E, Engelhardt, Frommhold, Hartung, Hermanek, Herrmann, Hossfeld, Junginger, Kirchner, Kreuser, Meyer, Müller, Pichlmaier, Queißer, Schlag, Schmoll, Stock, Wilke: (1996) Konsens der CAO, AOI und ARO zur Diagnostik und Therapie des primären Magenlymphoms. Onkologie, 19: 360-363 IF: 0,451, anteiliger IF: 0,0094

131. Dunn TA, Schmoll HJ, Grünwald V, Bokemeyer C, Casper J: (1996) Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer. ANTI-CANCER DRUG, 7: 1-5 IF: 1,397, anteiliger IF: 0,15525

132. Erlichman C, Fine S, Kerr I, Hoffmann W, Görg C, Schmoll HJ, Preusser P, Thuerlimann B, Gustavsson B: (1996) A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer. AM J CLIN ONCOL-CANC, 19: 26-31 IF: 0,921, anteiliger IF: 0,04387

133. Fels LM, Bokemeyer C, van Rhee J, Schmoll HJ, Stolte H: (1996) Evaluation of late nephrotoxicity in long-term survivors of Hodgkin's disease. ONCOLOGY-BASEL, 53: 73-78 IF: 2,097, anteiliger IF: 0,23305

134. Hartmann JT, Thiel I, Schmoll HJ, Einsele H, Kanz L, Bokemeyer C: (1996) Malignant fibrous histiocytoma of bone - review of thirteen cases. Oncol Rep, 3: 1-5 IF: 0,476, anteiliger IF: 0,03967

135. Rambusch EG, Schuppert F, Müller-Kunert E, Stöcker W, Bokemeyer C, Schmoll HJ, von zur Mühlen A: (1996) Zytokintherapie und Endokrinium: Ist es sinnvoll, mehr als die Schilddrüse zu untersuchen? Med Klin

Intensivmed Notfmed, 91: 59-65 IF: 0,468 anteiliger IF: 0,0312

136. Rüther U, Nunnensiek C, Sessler R, Stilz S, Ulshöfer T, Müller HAG, Bader H, Bokemeyer C, Schmoll HJ, Toomes H, Jipp P: (1996) Efficacy of antiestrogen treatment in a benign metastasizing leimyoma with paraneoplastic estradiol production. Oncol Rep, 3: 293-299 IF: 0,476, anteiliger IF: 0,01763

137. Schmoll HJ: (1996) Die Therapie von Keimzelltumoren: Modell für eine interdisziplinäre Behandlungsstrategie. Med Klin Intensivmed Notfmed, 3: 80-84 IF: 1,709 anteiliger IF: 1,709

138. Schmoll HJ: (1996) Development of Treatment for Advanced Colorectal Cancer: Infusional 5-FU and the role of new agents. EUR J CANCER, 32: S18-22 IF: 2,017, anteiliger IF: 2,017

139. Schmoll HJ, Bokemeyer C: (1996) Sequential intermediate high-dose chemotherapy in the primary treatment of poor risk testicular cancer. BONE MARROW TRANSPL, 18: 48-49 IF: 2,771, anteiliger IF: 1,3855

140. Hartmann J1, Thiel I, Schmoll H, Einsele H, Kanz L, Bokemeyer C. Malignant fibrous histiocytoma of bone - Review of thirteen cases. Oncol Rep. 1996 Sep;3(5):813-7.



141. Bamberg M, Schmoll HJ, Weißbach L, Beyer J, Bokemeyer C, Harstrick A, Höltl W, Souchon R, Vogler H: (1997) An interdiciplinary consensus conference on the diagnosis and therapy of testicular tumors. Strahlenther Onkol, 173: 397-406 IF: 2,5 anteiliger IF: 0,14286

142. Berkovic D, Grundel O, Berkovic K, Wildfang I, Hess CF, Schmoll HJ: (1997) Synergistic cytotoxic effects of either phospholipid analogues and ionizing radiation in human carcinoma cells. Radiother Oncol, 43: 293-301 IF: 1,924, anteiliger IF: 0,64127

143. Bokemeyer C, Franzke A, Hartmann JT, Schöber C, Arseniev L, Metzner B, Link H, Kanz L, Schmoll HJ: (1997) A Phase I/ II Study of Sequential, Dose-Escalated, High-Dose Ifosfamide plus Doxorubicin with Peripheral Blood Stem Cell Support for the Treatment of Patients with Advanced Soft Tissue Sarcomas. CANCER-AM CANCER SOC, 6: 1221-1227 IF: 3,296, anteiliger IF: 1,09856

144. Bokemeyer C, Nowak P, Haupt A, Metzner B, Köhne H, Hartmann JT, Kanz L, Schmoll HJ: (1997) Treatment of brain metastases in patients with testicular cancer. J CLIN ONCOL, 15: 1449-1454 IF: 7,878, anteiliger IF: 2,62574

145. Dunn TA, Schmoll HJ, Grünewald V, Bokemeyer C, Casper J: (1997) Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. INVEST NEW DRUG, 15: 109-114 IF: 0,543, anteiliger IF: 0,06035

146. Dunn T, Schmoll HJ, Grünewald V, Casper J, Bokemeyer C: (1997) Pre-clinical activity of taxol in nonseminomatous germ cell tumor cell lines and nude mouse xenografts. INVEST NEW DRUG, 15: 91-98 IF: 0,543, anteiliger IF: 0,06035

147. Harstrick A, Köhne CH, Hiddemann W, Preusser P, Berns T, Seeber S, Wilke H, Schmoll HJ: (1997) Modulation of 5-Flourouracil with Metotrexate and Low-dose N-(phosphonacety)-L-aspartete (PALA) in inactive advanced pancreatic carcinoma. ANN ONCOL, 8: 917-918 IF: 2,548, anteiliger IF: 0,84925

148. Hartmann JT, Candelaria M, Kuczyk MA, Schmoll HJ, Bokemeyer C: (1997) Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumors. EUR J CANCER, 33: 843-847 IF: 2,407, anteiliger IF: 0,2675

149. Hartmann JT, Schmoll HJ, Kuczyk MA, Candelaria M, Bokemeyer C: (1997) Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. ANN ONCOL, 8: 531-538 IF: 2,548, anteiliger IF: 0,28317

150. Hartmannn JT, Schmoll HJ, Thiel I, Kanz L, Bokemeyer C: (1997) Klinische Verlaufsbeobachtung von Patienten mit malignem fibrösen Histiozytom des Knochens und Übersicht zur chemotherapeutischen Behandlung. TUMORDIAGN THER, 1: Jan 34 IF: 0,148, anteiliger IF: 0,01645

151. Hartmann, Schmoll E, Bokemeyer C, Fety, Lucas, D´Agay, Schmoll HJ: (1997) Hepatic arterial infusion of the nitrosourea derivate fotemustine for the treatment of liver metastases from colorectal carcinoma. Oncol Rep, 4: 167-172 IF: 0,407, anteiliger IF: 0,13565

152. Köhne C, Harstrick A, Hiddemann W, Schöffski P, Wilke H, Bokemeyer C, Dörken B, Schmoll HJ: (1997) Modulation of 5-Flourouracil with

Metotrexate and Low-dose N-(phosphonacety)-L-aspartete in Patients with Advanced Colorectal Cancer. Results of a Phase II Study. EUR J CANCER, 33: 1896-1899 IF: 2,407, anteiliger IF: 0,80225

153. Köhne C, Wilke H, Hiddemann W, Bokemeyer C, Lohrmann HP, Bodenstein H, Preiss J, Rauschecker H, Hill H, Käufer C, Fischer JT, Ohl U, Urbanitz D, Balleisen L, Schmoll HJ: (1997) Phase II Evaluation of 5-Flourouracil plus Folinic acid and alpha 2b-interferon in metastatic colorectal cancer. ONCOLOGY-BASEL, 54: 98-101 IF: 2,141, anteiliger IF: 0,7136

154. Malek NP, Casper J, Looijenga LH, Strohmeyer T, Schmoll HJ, Nordheim A, Janknecht R: (1997) Quantification of additional short arms of chromosome 12 in germ cell tumors using the polymerase chain reaction. EUR J CANCER, 33: 1488-1494 IF: 2,407, anteiliger IF: 0,1605

155. Schmoll HJ: (1997) Prognostic factors for advanced seminoma - a solid basis for clinical trials (Editorial). EUR J CANCER, 9: 1347-1350 IF: 2,407, anteiliger IF: 2,407

156. Schmoll HJ, Bamberg M, Weißbach L: (1997) Interdisziplinäre Konsensus-Konferenz zur Diagnostik und Therapie von Hodentumoren. Onkologie, 20: 164-170 IF: 0,328, anteiliger IF: 0,10932

157. Schmoll HJ, Büchele T, Schöber C: (1997) The role of second line chemotherapy in colorectal cancer. Onkologie, 20: 288-294 IF: 0,328, anteiliger IF: 0,10932

158. Schöber C, Galanski M, Jörgensen M, Schmoll HJ: (1997) Management of endocrine pancreatic tumors. WIEN KLIN WOCHENSCHR, 147: 18-23 IF: 0,411, anteiliger IF: 0,13699

159. Seliger B, Dunn T, Schwenzer A, Casper J, Huber C, Schmoll HJ: (1997) Analysis of the MHC-Class I antigen presentation machinery in a human embryonal carcinoma cell line: evidence for suppression of TAP, LMP and MHC class I expression. SCAND J IMMUNOL, 46: 625-632 IF: 1,749, anteiliger IF: 0,58294

160. Weißbach L, Bamberg M, Schmoll HJ: (1997) Interdisciplinary consensus conference on diagnosis and therapy of testicular cancer. Urologe A, 36: 362-368 IF: 0,513, anteiliger IF: 0,17098

161. Hartmann J1, Schmoll E, Bokemeyer C, Fety R, Lucas C, Dagay L, Schmoll H Hepatic arterial infusion of the nitrosourea derivate fotemustine for the treatment of liver metastases from colorectal carcinoma. Oncol Rep. 1997 Jan-Feb;4(1):167-72.



162. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W: (1998) Salvagetherapie rezidivierter und refraktärer Hodentumoren. ONKOLOGE, 4: 541-546 IF: 0,1 anteiliger IF: 0,017

163. Beyer J, Schmoll HJ: (1998) Prognosefaktoren bei metastasierten seminomatösen und nichtseminomatösen Hodentumoren. ONKOLOGE, 4: 518-523 IF: 0,1 anteiliger IF: 0,05

164. Bokemeyer C, Berger CC, Hartmann JT, Kollmannsberger C, Schmoll HJ, Kuczyk MA, Kanz L: (1998) Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. BRIT J CANCER, 77: 1355-1362 IF: 3,036, anteiliger IF: 0,20244

165. Bokemeyer C, Gerl A, Harstrick A, Schmoll HJ: (1998) Therapie des fortgeschrittenen nichtseminomatösen Keimzelltumors. ONKOLOGE, 4: 532-540 IF: 0,1 anteiliger IF: 0,0333

166. Bokemeyer T, Harstrick A, Beyer J, Metzner B, Rüther U, Hartmann JT, Holstein K, Derigs HG, de Wit R, Casper J, Schöffski P, Kuhrer I, Illiger HJ, Kempf B, Reichle A, Foller A, Hossfeld DK, Fischer JT, Berdel WE, Gerhartz HH, Kirchner H, Pflüger KH, Ostermann H, Kanz L, Schmoll HJ: (1998) The use of dose-intensified chemotherapy in the treatment of metastatic non-seminomatous testicular germ cell tumors. German Testicular Cancer Study Group. SEMIN ONCOL, 25: 24-32 IF: 2,252, anteiliger IF: 0,75059

167. Dunn T, Schmoll HJ, Rie C, Hartmann K, Casper J: (1998) Production and pre-clinical significance of hematopoietic peptide growth factor (HPGF) in human non-seminomatous germ cell tumor (NSGCT) cell lines. J CANCER RES CLIN, 124: 435-443 IF: 1,183, anteiliger IF: 0,13147

168. Hartmann JT, Köhne CH, Schmoll HJ, Daikeler T, Kanz L, Bokemeyer C: (1998) Is continuous 24-hour infusion of 5-Flourouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? A phase II Study. ONCOLOGY-BASEL, 55: 320-325 IF: 2,858, anteiliger IF: 0,23821

169. Hartmann JT, Schmoll E, Bokemeyer C, Fety R, Lucas C, Giroux B, Schmoll HJ: (1998) Phase I Pharmacological Study of Intra-arterially Infused

Fotemustine for Colorectal Liver Metastases. EUR J CANCER, 34: 87-91 IF: 2,743, anteiliger IF: 0,91424

170. Köhne CH, Schöffski P, Wilke H, Kaufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstrick A, Bade J, Horster A, Schubert U, Hecker H, Dörken B, Schmoll HJ: (1998) Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J CLIN ONCOL, 16: 418-426 IF: 8,228, anteiliger IF: 2,74239

171. Kollmannsberger C, Beyer J, Droz JP, Harstrick A, Hartmann JT, Biron P, Flechon A, Schöffski P, Kuczyk M, Schmoll HJ, Kanz L, Bokemeyer C: (1998) Secondary leukemia following high cumulative doses for Etoposide in Patients treated for advanced germ cell tumors. J CLIN ONCOL, 16: 3386-3391 IF: 8,228, anteiliger IF: 0,27432

172. Korfel A, Scheulen ME, Schmoll HJ, Gründel O, Harstrick A, Knoche M, Fels LM, Skorzec M, Bach F, Baumgart J, Saß G, Seeber S, Thiel E, Berdel WE: (1998) Phase I Clinical and Pharmacokinetic Study of Titanocene Dichloride in adults with advanced solid tumors. CLIN CANCER RES, 4: 2701-2708 IF: 2,941, anteiliger IF: 0,08171

173. Schmoll HJ: (1998) Is there a standard adjuvant treatment for colon cancer? (Editorial). EUR J CANCER, 34: 1659-1663 IF: 2,743, anteiliger IF: 2,743

174. Schmoll HJ: (1998) Is there a standard adjuvant treatment for rectal cancer? (Editorial). EUR J CANCER, 34: 1827-1835 IF: 2,743, anteiliger IF: 2,743

175. Schmoll HJ, Beyer J: (1998) Prognostic factors in metastatic germ cell tumors. SEMIN ONCOL, 25: 174-186 IF: 2,252, anteiliger IF: 1,126

176. Schmoll HJ, Weißbach L, Bamberg M: (1998) Editorial: Therapie des Hodentumors: das Zauberwort heißt Interdisziplinarität. ONKOLOGE, 4: 471-472 IF: 0,1 anteiliger IF: 0,0333


177. Bokemeyer C, Gerl A, Schöffski P, Harstrick A, Niederle N, Beyer J, Casper J, Schmoll HJ: (1999) Gemcitabine in patients with relapsed or Cisplatin-refractory testicular cancer. J CLIN ONCOL, 17: 512-516 IF: 7,963, anteiliger IF: 2,65407

178. Bokemeyer C, Kollmannsberger C, Harstrick A, Beyer J, Gerl A, Casper J, Metzner B, Hartmann JT, Schmoll HJ, Kanz L: (1999) Treatment of patients with Cisplatin-refractory testicular germ-cell cancer. Int J Cancer, 83: 848-851 IF: 3,545, anteiliger IF: 0,14774

179. Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C: (1999) First-Line High-Dose Chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J CLIN ONCOL, 17: 3450-3456 IF: 7,963, anteiliger IF: 0,29498

180. Dempke W, Behrmann C, Schöber C, Büchele T, Grothey A, Schmoll HJ: (1999) Diagnostisches und therapeutisches Management der oberen Einflussstauung. Med Klin Intensivmed Notfmed, 94: 681-684 IF: 0,5 anteiliger IF: 0,1666

181. Dempke W, Büchele T, Wolf HH, Grothey A, Schmoll HJ: (1999) Diagnostik und Therapie maligner Pleura- und Perikardergüsse. Onkologie, 22: 526-529 IF: 0,382, anteiliger IF: 0,12732

182. Dempke W, Voigt W, Grothey A, Schmoll HJ: (1999) Preferential repair of the N-ras gene in K562 cells after exposure to cisplatin. ANTI-CANCER DRUG, 10: 545-549 IF: 1,594, anteiliger IF: 0,53128

183. Fossa SD, Bokemeyer C, Gerl A, Culine S, Jones WG, Mrad GM, Germa-Luch JR, Pont J, Schmoll HJ, Tjulandin S: (1999) Treatment outcome of patients with brain metastases from malignant germ cell tumors. CANCER-AM CANCER SOC, 85: 988-997 IF: 3,632, anteiliger IF: 0,15136

184. Grothey A, Voigt W, Schöber C, Müller T, Dempke W, Schmoll HJ: (1999) The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J CANCER RES CLIN, 125: 166-173 IF: 1,052, anteiliger IF: 0,35063

185. Hartmann JT, Albrecht C, Schmoll HJ, Kuczyk MA, Kollmannsberger C, Bokemeyer C: (1999) Long-term effects on sexual function and fertility after treatment of testicular cancer. BRIT J CANCER, 80: 801-807 IF: 3,282, anteiliger IF: 0,27355

186. Kellner O, Dempke W, Schmoll HJ: (1999) Glukose-Infusionen - eine mögliche effektive Therapieoption bei der Ifosfamid-induzierten Enzephalopathie. Dtsch Med Wochenschr, 124: 1086-1087 IF: 0,684, anteiliger IF: 0,22798

187. Schmoll HJ: (1999) Treatment of testicular tumours based on risk factors. CURR OPIN UROL, 9: 431-438 IF: 2,59 anteiliger IF: 2,59

188. Schmoll HJ: (1999) Standards in der Behandlung kolorektaler Karzinome - Wunsch und Wirklichkeit. ONCOLOGY-BASEL, 99: 6-7 IF: 2,684, anteiliger IF: 2,684

189. Schmoll HJ, Büchele T, Grothey A, Dempke W: (1999) Where do we stand with 5-FU? SEMIN ONCOL, 26: 589-605 IF: 2,986, anteiliger IF: 0,99523


190. Brieger P, Wolf HH, Schmoll HJ, Marneros A: (2000) Manic episode in an ifosfamide-treated patient. GEN HOSP PSYCHIAT, 22: 52-53 IF: 1,512, anteiliger IF: 0,25205

191. Büchele T, Grothey A, Schmoll HJ: (2000) Neue Perspektiven mit neuen Zytostatika in der Behandlung des kolorektalen Karzinoms. ONKOLOGE, 6: 410-419 IF: 0,12 anteiliger IF: 0,04

192. Dempke W, Voigt W, Grothey A, Hill BT, Schmoll HJ: (2000) Cisplatin resistance and oncogenes - a review. ANTI-CANCER DRUG, 11: 225-236 IF: 1,57, anteiliger IF: 0,52328

193. Dempke W, von Poblozki A, Grothey A, Schmoll HJ: (2000) Human hematopoietic growth factors: old lessons and new perspectives. ANTICANCER RES, 20: 5155-5164 IF: 1,331, anteiliger IF: 0,44362

194. Grothey A, Kegel T, Dempke W, Schmoll HJ: (2000) Systemische Therapie des hepatozellulären Karzinoms. ONKOLOGE, 6: 327-335 IF: 1,41 anteiliger IF: 0,47

195. Kellner O, Voigt W, Schneyer U, Dempke W, Schmoll HJ: (2000) HCG-induced hyperthyreosis in germ cell cancer. ANTICANCER RES, 20: 5135-8 IF: 1,331, anteiliger IF: 0,44362

196. Kollmannsberger C, Nichols C, Bamberg M, Hartmann JT, Schleucher N, Beyer J, Schöffski P, Gerigs G, Rüther U, Bohlke I, Schmoll HJ, Kanz L, Bokemeyer C: (2000) First-Line High-Dose chemotherapy + radiation therapy in patients with metastatic germ-cell cancer and brain metastases. ANN ONCOL, 11: 553-559 IF: 3,249, anteiliger IF: 0,09847

197. Schmiegel W, Adler G, Frühmorgen P, Fölsch U, Greaven U, Layer P, Petrasch S, Porschen R, Pox C, Sauerbruch T, Schmoll HJ, Zeitz M: (2000) Kolorektales Karzinom: Prävention und Früherkennung in der asymptomatischen Bevölkerung - Vorsorge bei Risikopatienten - Endoskopische Diagnostik, Therapie und Nachsorge von Polypen und Karzinomen. Z Gastroenterol, 38: 49-75

IF: 0,887, anteiliger IF: 0,02957

198. Schmoll HJ: (2000) Aktive spezifische Immunotherapie (ASI) beim Kolonkarzinom. Strahlenther Onkol, 176: 47-48 IF: 2,846, anteiliger IF: 2,846

199. Schmoll HJ, Krege S, Souchon R: (2000) Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren: Ergebnisse einer Update-Konferenz auf der Grundlage evidenzbasierter Medizin. Onkologie, 23: 603-613 IF: 0,64, anteiliger IF: 0,21331

200. Souchon R, Krege S, Schmoll HJ, Albers P, Veyer J, Bokemeyer C, Claßena J, Dieckmann KP, Hartmann M, Heidenreich A, Höltl W, Kliesch S, Köhrmann KU, Kuczyk M, Schmidberger H, Weinknecht S, Winter E, Wittekind C, Bamberg M: (2000) Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren. Strahlenther Onkol, 176: 388-405 IF: 2,846, anteiliger IF: 0,05582

201. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA: (2000) Final results of a randomized phase II trial of sequential high-dose methotrexate, flourouracil, and doxorubin versus etoposide, leucovorin and flourouracil versus infusion fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J CLIN ONCOL, 18: 2648-2657 IF: 8,773, anteiliger IF: 0,19499

202. Voigt W, Bulankin A, Müller T, Schöber C, Grothey A, Hoang-Vu C, Schmoll HJ: (2000) Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. CLIN CANCER RES, 6: 2087-2093 IF: 4,643, anteiliger IF: 1,54751

203. von Poblozki A, Dempke W, Schmoll HJ: (2000) Carboxypeptidase-G2-Rescue bei einer Patientin mit Methotrexat-induziertem Nierenversagen. Med Klin Intensivmed Notfmed, 95: 457-460 IF: 0,39 anteiliger IF: 0,13


204. Bokemeyer C, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Schmoll HJ, Kanz L, Einhorn L, Nichols CR, Hartmann JT: (2001) Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome. CANCER-AM CANCER SOC, 91: 1394-1401


205. Dempke W, Rie C, Grothey A, Schmoll HJ: (2001) Cyclooxygenase-2: a novel target for cancer chemotherapy? J CANCER RES CLIN, 127: 411-417 IF: 2,194, anteiliger IF: 0,73126

206. Dempke W, Schmoll HJ: (2001) Mögliche neue Indikationen für die Therapie mit Erythropetin. Med Klin Intensivmed Notfmed, 96: 467-474 IF: 0,5 anteiliger IF: 0,25

207. Dempke W, von Poblozki A, Kellner O, Wolf HH, Schmoll HJ: (2001) Hämorrhagische Diathese als Erstsymptom eines Magenkarzinoms. WIEN KLIN WOCHENSCHR, 112: 1053-1058 IF: 0,646, anteiliger IF: 0,21531

208. Fittkau M, Gerlach R, Schmoll HJ: (2001) Protective effect of oral phosphatidylcholine on radiation-induced release of intestinal peptidases in rats. J CANCER RES CLIN, 127: 444 IF: 2,194, anteiliger IF: 0,73126

209. Fittkau M, Grothey A, Gerlach R, Schmoll HJ: (2001) A low dose of ionizing radiation increases luminal release of intestinal peptidases in rats. J CANCER RES CLIN, 127: 96-100 IF: 2,194, anteiliger IF: 0,73126

210. Fizazi K, Tjulandin S, Salvioni R, Germa-Luch JR, Bouzy J, Ragan D, Bokemeyer C, Gerl A, Flechon A, de Bono JS, Stenning S, Horwich A, Pont J, Albers P, De Giorgi U, Bower M, Bulanov A, Pizzocaro G, Aparicio J, Nichols CR, Theodore C, Hartmann JT, Schmoll HJ, Kaye SB, Culine S, Droz JP, Mahe C: (2001) Viable malignant cells after primary Chemotherapy for disseminated nonseminomatous germ cell tumors: Prognostic factors and role of postsurgery chemotherapy - results from an international study group. J CLIN ONCOL, 19: 2647-2657 IF: 8,53, anteiliger IF: 0,11376

211. Grothey A, Schmoll HJ: (2001) New Chemotherapy approaches in colorectal cancer. CURR OPIN ONCOL, 13: 275-286 IF: 2,156 anteiliger IF: 1,078

212. Hartmann JT, Einhorn L, Nichols CR, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Schmoll HJ, Kanz L, Bokemeyer C: (2001) Second-line chemotherapy in patients with released extragonadal nonseminomatous germ cell tumors: Results of an international multicenter analysis. J CLIN ONCOL, 19: 1641-1648 IF: 8,53, anteiliger IF: 0,28439

213. Hoff PM, Cassidy J, Schmoll HJ: (2001) The evolution of Fluoropyrimidine Therapy: From Intravenous to Oral. ONCOLOGIST, 6: 3-11 IF: 1,203 anteiliger IF: 0,401

214. Kellner O, Krüger W, Schmoll HJ: (2001) Standardmanagement von Fieber unklarer Genese (FUO) bei hämatologischen oder onkologischen Patienten in der Neutropenie. PHARMAZIE, 3: 03. Apr


215. Krege S, Souchon R, Schmoll HJ: (2001) Interdisciplinary consensus on Diagnosis and Treatment of Testicular Germ Cell Tumors: Result of an Update Conference on Evidence-Based Medicine (EBM). Eur Urol, 40: 372-391 IF: 2,304, anteiliger IF: 0,76792

216. Krege S, Souchon R, Schmoll HJ: (2001) Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren. Ergebnisse einer Update-Konferenz auf Grundlage evidensbasierter Medizin. Urologe A, 2: 137-147 IF: 0,497, anteiliger IF: 0,16565

217. Rades D, Kühnel G, Wildfang I, Bömer AR, Schmoll HJ, Knapp W, Karstens JH: (2001) Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. ANN ONCOL, 12: 1605-1609 IF: 3,153, anteiliger IF: 0,21024

218. Rick O, Bokemeyer C, Beyer J, Hartmann JT, Schwella N, Kingreen D, Neureither S, Metzner B, Casper J, Wandt H, Hartmann F, Schmoll HJ, Derigs G, Gerl A, Berdel W, Kanz L, Siegert W: (2001) Salvage treatment with paclitaxel, ifosfamide and cisplatin (TIP) plus high-dose carboplatin, etoposide and thiotepa (CET) followed by autologous stem cell rescue in patients with relapsed or refractory germ cell cancer. J CLIN ONCOL, 19: 81-88 IF: 8,53, anteiliger IF: 0,18959

219. Schmoll HJ: (2001) Kolorektale Karzinome. Onkologie, 24: 1-8 IF: 0,573, anteiliger IF: 0,573

220. Schmoll HJ, Cassidy J: (2001) Integrating Oxaliplatin into the Management of Colorectal Cancer. ONCOLOGIST, 6: 24-28 IF: 1,203 anteiliger IF: 0,6015

221. Wolf HH, Förster W, Schöber C, Grothey A, Dempke W, Schmoll HJ: (2001) Cyclooxigenase-2-inhibitors in colon cancer. Onkologie, ?: # IF: 0,573, anteiliger IF: 0,19098


222. Bokemeyer C, Nichols CR, Droz JP, Schmoll HJ, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Kanz L, Einhorn L, Hartmann JT: (2002) Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J CLIN ONCOL, 20: 1864-73. 11919246 IF: 9,868, anteiliger IF: 0,329

223. Fittkau M, Gerlach R, Schmoll HJ: (2002) Phosphatidylcholine does not protect rats against 5-fluorouracil/ folinic acid-induced damage of the intestinal

luminal mucosa. J CANCER RES CLIN, 128: 80-84 IF: 2,197, anteiliger IF: 0,73226

224. Grothey A, Kellermann L, Schmoll HJ: (2002) [Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms]. Med Klin Intensivmed Notfmed, 97: 270-7. 12078387 IF: 0,365 anteiliger IF: 0,1217

225. Krüger W, Wolf HH, Voigt W, Skibbe T, Schmoll HJ: (2002) Detection of an occult B-cell lymphoma in the donor's bone marrow prior to HLA-matched sibling transplantation. J HEMATOTH STEM CELL, 11: 169-170 IF: 1,628, anteiliger IF: 0,54261

226. Mantovani L, Hasenclever D, Krahl R, Ponisch W, Herold M, Pasold R, Fiedler F, Dolken G, Kampfe D, Schmoll HJ, Subert R, Kubel M, Niederwieser D, Helbig W: (2002) Intermediate-dose cytarabine treatment delivered at moderate infusion rates for de novo acute myeloid leukemia-results of a phase I-II study. Leuk Lymphoma, 43: 265-74. 11999557 IF: 1,335, anteiliger IF: 0,03709

227. Schmoll HJ: (2002) Is there a role of high-dose chemotherapy in lymphoma and solid tumours: The present state of the art. CRIT REV ONCOL HEMAT, 41: 127-128 IF: 2,758, anteiliger IF: 2,758

228. Schmoll HJ: (2002) The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions. SEMIN ONCOL, 29(5 Suppl 15): 34-9. 12422306 IF: 3,5, anteiliger IF: 3,5

229. Schmoll HJ: (2002) Extragonadal germ cell tumors. ANN ONCOL, 13: 265-72. 12401700 IF: 3,114, anteiliger IF: 3,114

230. Van Cutsem E, Dicato M, Wils J, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Johnston P, Kerr D, Koehne CH, Labianca R, Minsky B, Nordlinger B, Roth A, Rougier P, Schmoll HJ: (2002) Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001). EUR J CANCER, 38: 1429-36. 12110487 IF: 3,562, anteiliger IF: 1,18721

231. Voigt W, Behrmann C, Schlüter A, Bläser F, Wunderlich D, Harba A, Kegel T, Grothey A, Schmoll E, Schmoll HJ: (2002) Hepatic transcatheter arterial chemoembolisation in refractory liver metastasis of colorectal cancer with Mitomycin C, Interferon-ALPHA2b and Dexamethasone mixed with Amilomer DSM 45/25 (Sperex®) followed by Oxaliplatin, Folinic acid and 5-Fluorouracil - feasibility and preliminary results. Onkologie, 25: 158-164 IF: 0,855, anteiliger IF: 0,28497

232. Voigt W, Behrmann C, Schlueter A, Kegel T, Grothey A, Schmoll HJ: (2002) A new chemoembolization protocol in refractory liver metastasis of

colorectal cancer--a feasibility study. Onkologie, 25: 158-64. 12006767 IF: 0,855, anteiliger IF: 0,28497


233. Arnold D, Grothey A, Schmoll HJ: (2003) Neue Entwicklungen in der systemischen Therapie des fortgeschrittenen Kolonkarzinoms. ONKOLOGE, 9: 847-859 IF: 1,41 anteiliger IF: 0,47

234. Bokemeyer C, Schleucher N, Metzner B, Thomas M, Rick O, Schmoll HJ, Kollmannsberger C, Boehlke I, Kanz L, Hartmann JT: (2003) First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial. BRIT J CANCER, 89: 29-35. 12838296 IF: 3,894, anteiliger IF: 0,16228

235. Kohne CH, Wils J, Lorenz M, Schoffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg C, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Ruckle H, Lichnitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ: (2003) Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J CLIN ONCOL, 21: 3721-8. IF: 10,864, anteiliger IF: 3,62097

236. Kollmannsberger C, Schleucher N, Rick O, Metzner B, Hartmann JT, Schoffski P, Beyer J, Casper J, Sosada M, Schmoll HJ, Bohlke I, Meisner C, Kanz L, Bokemeyer C: (2003) Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support. EUR J CANCER, 39: 775-82. 12651203 IF: 3,694, anteiliger IF: 0,10263

237. Mueller T, Voigt W, Simon H, Fruehauf A, Bulankin A, Grothey A, Schmoll HJ: (2003) Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. CANCER RES, 63: 513-21. 12543810 IF: 8,649, anteiliger IF: 2,88271

238. Paschke R, Kalbitz J, Paetz C, Luckner M, Mueller T, Schmoll HJ, Mueller H, Sorkau E, Sinn E: (2003) Cholic acid-carboplatin compounds (CarboChAPt) as models for specific drug delivery: synthesis of novel carboplatin analogous derivatives and comparison of the cytotoxic properties with corresponding cisplatin compounds. J INORG BIOCHEM, 94: 335-42. 12667704 IF: 2,343, anteiliger IF: 0,11159

239. Paschke R, Paetz C, Mueller T, Schmoll HJ, Mueller H, Sorkau E, Sinn E: (2003) Biomolecules linked to transition metal complexes-new chances for chemotherapy. CURR MED CHEM, 10: 2033-44. 12871101 IF: 4,409, anteiliger IF: 0,29399

240. Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R: (2003) Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J CLIN ONCOL, 21: 3098-104. 12915600 IF: 10,864, anteiliger IF: 0,90551

241. Schmoll HJ: (2003) Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer. ANTI-CANCER DRUG, 14: 695-702. 14551502 IF: 1,938, anteiliger IF: 1,938

242. Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schoffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C: (2003) Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J CLIN ONCOL, 21: 4083-91. IF: 10,864, anteiliger IF: 3,62097


243. Arnold D, Schmoll HJ: (2004) Palliative Systemtherapie beim metastasierten Ösophaguskarzinom. Sind neue Therapieansätze in Sicht? ONKOLOGE, 10: 1202-1214 IF: 1,41 anteiliger IF: 0,705

244. Bokemeyer C, Kollmannsberger C, Stenning S, Hartmann JT, Horwich A, Clemm C, Gerl A, Meisner C, Ruckerl CP, Schmoll HJ, Kanz L, Oliver T: (2004) Metastatic seminoma treated with either single agent carboplatin or cisplatin based combination chemotherapy: a pooled analysis of two randomised trials. BRIT J CANCER, 91: 683-687 IF: 3,742, anteiliger IF: 0,12476

245. Fittkau M, Voigt W, Holzhausen HJ, Schmoll HJ: (2004) Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats. J CANCER RES CLIN, 25: 388-394 15160289 IF: 2,409, anteiliger IF: 0,80292

246. Grothey A, Sargent D, Goldberg RM, Schmoll HJ: (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J CLIN ONCOL, 1: 1209-1214 IF: 9,835, anteiliger IF: 3,27801

247. Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A: (2004) Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patiens with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. ANN HEMATOL, 83: 498-503 IF: 1,292, anteiliger IF: 0,03077

248. Jordan K, Kellner O, Kegel T, Schmoll HJ, Grothey A: (2004) Phase II Trial of Capecitabine/ Irinotecan and Capecitabine/ Oxaliplatin in Advanced Colorectal Cancer. CLIN COLORECTAL CANC, 4: 46-50 IF: 2,0 anteiliger IF: 0,2222

249. Kegel T, Schmoll HJ: (2004) Systemische Chemotherapie neuroendokriner Tumoren. ONKOLOGE, 10: 621-633 IF: 0,1 anteiliger IF: 0,05

250. Rades D, Fehlauer F, Stalpers LJ, Wildfang I, Zschenker O, Schild SE, Schmoll HJ, Karstens JH, Alberti W: (2004) A prospective evaluation of two radiotherapy schedules with 10 versus 20 fractions for the treatment of metastatic spinal cord compression: final results of a multicenter study. CANCER-AM CANCER SOC, 101: 2687-2692 IF: 1,654, anteiliger IF: 0,07878

251. Schmiegel W, Pox C, Adler G, Fleig W, Fölsch UR, Frühmorgen P, Graeven U, Hohenberger W, Holstege A, Junginger T, Kühlbacher T, Porschen R, Propping P, Riemann JF, Sauer R, Sauerbruch T, Schmoll HJ, Zeitz M, Selbmann HK: (2004) S3-Leitlinienkonferenz "Kolorektales Karzinom". Z Gastroenterol, 10: 1129-1177 IF: 1, anteiliger IF: 0,01961

252. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE, De Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G, De Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O, Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J, Clemm S, Culine S, De Wit M, Derigs HG, Dieckmann KP, Flasshove M, Garcia Del Muro X, Gerl A, Germa-Lluch JR, Hartmann M, Heidenreich A, Hoeltl W, Joffe J, Jones W, Kaiser G, Klepp O, Kliesch S, Kisbenedek L, Koehrmann KU, Kuczyk M, Laguna MP, Leiva O, Loy V, Mason MD, Mead GM, Mueller RP, Nicolai N, Oosterhof GO, Pottek T, Rick O, Schmidberger H, Sedlmayer F, Siegert W, Studer U, Tjulandin S, Von der Maase H, Walz P, Weinknecht S, Weissbach L, Winter E, Wittekind C: (2004) European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). ANN ONCOL, 15: 1377-99. 15319245 IF: 4,335, anteiliger IF: 1,44486


253. Arnold D, Schmoll HJ: (2005) (Neo-)adjuvant treatments in colorectal cancer. ANN ONCOL, 16: ii133-ii140 IF: 4,319, anteiliger IF: 2,1595

254. Diaz-Rubio E, Schmoll HJ: (2005) Introduction. Critical role of anti-angiogenesis and VEGF inhibition in colorectal cancer. ONCOLOGY-BASEL, 69: 1-3 IF: 1,985, anteiliger IF: 0,9925

255. Diaz-Rubio E, Schmoll HJ: (2005) The future development of bevacizumab in colorectal cancer. ONCOLOGY-BASEL, 69: 34-45 IF: 1,985, anteiliger IF: 0,9925

256. Hochster H, Kettner E, Kroning H, Becker K, Lordick F, Ramanathan RK, Macdonald J, Hong S, John W, Schmoll HJ: (2005) Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer. CLIN COLORECTAL CANC, 5: 257-262 IF: 2,0 anteiliger IF: 0,66666

257. Jordan K, Grothe W, Schmoll HJ: (2005) Paravasation von Zytostatika: Prävention und Therapie. Dtsch Med Wochenschr, 130: 33-37 IF: 0,653, anteiliger IF: 0,21764

258. Jordan K, Grothey A, Grothe W, Kegel T, Wolf HH, Schmoll HJ: (2005) Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy. EUR J HAEMATOL, 74: 263-266 IF: 2,004, anteiliger IF: 0,66793

259. Jordan K, Grothey A, Kegel T, Fibich C, Schoeber C, Schmoll HJ: (2005) Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting. Onkologie, 28: 88-92 IF: 1,206, anteiliger IF: 0,40196

260. Jordan K, Hinke A, Grothey A, Schmoll HJ: (2005) Granisetron versus tropisetron for prophylaxis of acute chemothrapy-induced emesis: a pooled analysis. Support Care Cancer, 31: 26-31 IF: 1,59, anteiliger IF: 0,52995

261. Jordan K, Kasper C, Schmoll HJ: (2005) Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. EUR J CANCER, 41: 199-205 IF: 3,706, anteiliger IF: 1,23521

262. Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, Jackisch C, Werner C, Ziske C, Kirchner H, Metzner B, Souchon R, Ruffert U, Schütt G, Pollmanns A, Schmoll HJ, Middecke C, Baltzer J, Schrader I, Wiebringhaus H, Ko Y, Rösel S, Schwenzer T, Wernet P, Hinke A, Bender HG, Frick M, West GSG: (2005) Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet, 366: 1935-44 16325695


263. Pico JL, Rosti G, Kramar A, Wandt H, Kza V, Salvioni R, Theodore C, Lelli G, Siegert W, Horwich A, Marangolo M, Linkesch W, Pizzocaro G, Schmoll HJ, Bozy J, Droz JP, Biron P: (2005) A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. ANN ONCOL, 16: 1152-1159 IF: 4,319, anteiliger IF: 0,096

264. Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D, Kunstlinger F, Mentha G, Nordlinger B, Patt Y, Primrose J, Roh M, Rougier P, Ruers T, Schmoll HJ, Valls C, Vauthey NJ, Cornelis M, Kahan JP: (2005) OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer. J CLIN ONCOL, 23: 7125-7134 IF: 11,81, anteiliger IF: 0,23161

265. Rennicke A, Voigt W, Mueller T, Fruehauf A, Schmoll HJ, Beyer C, Dempke W: (2005) Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP. ANTICANCER RES, 25: 1147-55 15868958 IF: 1,604, anteiliger IF: 0,10695

266. Schmiegel W, Pox C, Adler G, Fleig W, Folsch UR, Fruhmorgen P, Graeven U, Hohenberger W, Holstege A, Kuhlbacher T, Proschen R, Propping P, Riemann JF, Sauer R, Sauberbruch T, Schmoll HJ, Zeitz M, Selbmann He: (2005) S3-guideline conference "Colorectal Cancer" 2004. Dtsch Med Wochenschr, 8; 130 (Suppl. 1): S5-53 IF: 0,653, anteiliger IF: 0,01361

267. Voigt W, Kegel T, Weiss M, Mueller T, Simon H, Schmoll HJ: (2005) Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J CANCER RES CLIN, 131: 585-590 IF: 2,503, anteiliger IF: 0,83425

268. Birgegård G1, Aapro MS, Bokemeyer C, Dicato M, Drings P, Hornedo J, Krzakowski M, Ludwig H, Pecorelli S, Schmoll H, Schneider M, Schrijvers D, Shasha D, Van Belle S. Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology. 2005;68 Suppl 1:3-11.

IF: 1,572 anteilige IF: 0,04366


269. Arnold D, Peinert S, Voigt W, Schmoll HJ: (2006) Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. ONCOLOGIST, 11: 602-611


270. Arnold D, Siewczynski R, Schmoll HJ: (2006) The integration of targeted agents into systemic therapy of metastatic colorectal cancer. ANN ONCOL, 17: x122-x128 IF: 5,179, anteiliger IF: 1,72616

271. Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Schoeffski P, Schmoll H, Van Cutsem E, Koehne CH: (2006) Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? EUR J CANCER, 42: 42-49 IF: 4,167, anteiliger IF: 0,19847

272. Jordan K, Voigt W, Schmoll HJ: (2006) Chemotherapy induced nausea and vomiting - a practical treatment approach. Dtsch Med Wochenschr, Aug 25; 131 (34-35): 1869-1872 IF: 0,584, anteiliger IF: 0,19465

273. Krege S, Boergermann C, Baschek R, Hinke A, Pottek T, Kliesch S, Dieckmann KP, Albers P, Knutzen B, Weinknecht S, Schmoll HJ, Beyer J, Ruebben H: (2006) Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). ANN ONCOL, 17: 276-280 IF: 5,179, anteiliger IF: 0,15697

274. Mueller LP, Luetzkendorf J, Mueller T, Reichelt K, Simon H, Schmoll HJ: (2006) Presence of mesenchymal stem cells in human bone marrow after exposure to chemotherapy: evidence of resistance to apoptosis induction. STEM CELLS, 24: 2753-65 16931776 IF: 7,924, anteiliger IF: 2,64107

275. Mueller T, Mueller LP, Luetzkendorf J, Voigt W, Simon H, Schmoll HJ: (2006) Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance. TUMOR BIOL, 27: 71-83 16557044 IF: 2,407, anteiliger IF: 0,80225

276. Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K, von Pawel J, Giezek H, Ahmed T, Chan CY: (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. ANN ONCOL, 17: 1000-1006 IF: 5,179, anteiliger IF: 1,72616

277. Schmoll HJ, Arnold D: (2006) Update on capecitabine in colorectal cancer. ONCOLOGIST, 11: 1003-1009 IF: 5,206, anteiliger IF: 2,603

278. van Cutsem E, Dicato M, Arber N, Benson A, Cunningham D, Diaz-Rubio E, Glimelius B, Goldberg R, Haller D, Haustermans K, Koo-Kang Y, Labianca R, Lang I, Minsky B, Nordlinger B, Roth A, Rougier P, Schmoll HJ, Sobrero A, Tabernero J, Szawlowski A, van de Velde C: (2006) The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal

Cancer, Barcelona, 2005. ANN ONCOL, 17: vi 13-18 IF: 5,179, anteiliger IF: 0,08633

279. Voigt W, Kegel T, Maher G, Jordan K, Mueller L, Schmoll HJ: (2006) Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third-line salvage chemotherapy induced an unexpected dramatic response in highly platinum refractory germ-cell cancer. ANN ONCOL, 17: 531-533 IF: 5,179, anteiliger IF: 1,72616


280. Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Schöffski P, Schmoll H, Van Cutsem E, Köhne CH: (2007) Corrigendum to "Does a patient's self-reproted health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?". EUR J CANCER, 43: 633 IF: 4,454, anteiliger IF: 0,21214

281. Jordan K, Grothe W, Schmoll HJ: (2007) Zytostatikaparavasate: Prophylaxe und Therapie. Onkologie, 6: 55-58 IF: 1,227, anteiliger IF: 0,40896

282. Jordan K, Hinke A, Grothey A, Voigt W, Arnold D, Wolf HH, Schmoll HJ: (2007) A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer, 15: 1023-33 17205281 IF: 2,122, anteiliger IF: 0,70726

283. Jordan K, Schmoll HJ, Aapro MS: (2007) Comparative activity of antiemetic drugs. CRIT REV ONCOL HEMAT, 61: 162-175 IF: 4,632, anteiliger IF: 1,54431

284. Jordan K, Sippel C, Schmoll HJ: (2007) Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. ONCOLOGIST, 12: 1143-1150 IF: 4,876, anteiliger IF: 1,62517

285. Lorch JH, Thomas TO, Schmoll HJ: (2007) Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. CANCER RES, 15: 727-734 IF: 7,672, anteiliger IF: 2,55708

286. Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ: (2007) Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J CLIN ONCOL, 25: 4217-23 17548840


287. Punt CJ, Buyse M, Koehne CH, Hohenberger P, Labianca R, Schmoll HJ, Pahlman A, Douillard JY: (2007) Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. JNCI-J NATL CANCER I, 99: 998-1003 IF: 15,678, anteiliger IF: 0,87117

288. Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, de Braud F, Hill M, Sirzen F, Haller DG: (2007) Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J CLIN ONCOL, 1: 102-109 IF: 15,484, anteiliger IF: 5,16082

289. Schmoll HJ, Sargent D: (2007) Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard? Lancet, 370: 105-107 IF: 28,638, anteiliger IF: 14,319

290. Schmoll HJ, Sargent D: (2007) CAIRO and FOCUS - Author's reply. Lancet, 370: 1905 IF: 28,638, anteiliger IF: 14,319

291. Schmoll HJ, Schmiegel W: (2007) VII. Interdisziplinärer Expertenworkshop 2007 "Gastrointestinale Tumore" - Zusammenfassung. Onkologie, 30: 27 IF: 1,227, anteiliger IF: 0,6135

292. Verslype C, Van Cutsem E, Dicato M, Cascinu S, Cunningham D, Diaz-Rubio E, Glimelius B, Haller D, Haustermans K, Heinemann V, Hoff P, Johnston PD, Kerr D, Labianca R, Louvet C, Minsky B, Moore M, Nordlinger B, Pedrazzoli S, Roth A, Rothenberg M, Rougier P, Schmoll HJ, Tabernero J, Tempero M, van de Velde C, Van Laethem JL, Zalcberg J: (2007) The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona 2006. ANN ONCOL, 18: vii1-vii10 IF: 4,875, anteiliger IF: 0,06251

293. Voigt W, Maher G, Wolf HH, Schmoll HJ: (2007) Human chorionic gonadotropin-induced hyperthyroidism in germ cell cancer--a case presentation and review of the literature. Onkologie, 30: 330-4 17585415 IF: 1,227, anteiliger IF: 0,40896


294. Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, Martoni A, Grothey A, Hinke A, Schmiegel W, Schmoll HJ, Porschen R: (2008) Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: A pooled

analysis of randomized trials. J CLIN ONCOL, 20: 5910-5917 IF: 17,157, anteiliger IF: 0,57201

295. Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Martoni A, Grothey A, Hinke A, Schmiegel W, Schmoll HJ: (2008) The combination of oxaliplatin with capecitabine or 5-fluorouracil (5-FU)/ leucovorin in patients with metastastic colorectal cancer (MCRC): a pooled analysis of randomized phase II-III trials. J CLIN ONCOL, 26: 5910-5917 IF: 17,157, anteiliger IF: 5,71843

296. Arkenau HT, Graeven U, Kubicka S, Grothey A, Englisch-Fritz C, Kretzschmar A, Greil R, Freier W, Seufferlein T, Hinke A, Schmoll HJ, Schmiegel W, Porschen R, Colorectal Study Group AIO: (2008) Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. CLIN COLORECTAL CANC, 7: 60-4 18279579 IF: 2,724, anteiliger IF: 0,07568

297. Arnold D, Höhler T, Dittrich C, Lordick F, Seufferlein T, Riemann J, Wöll E, Herrmann T, Zubel A, Schmoll HJ: (2008) Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. ANN ONCOL, 19: 1442-9 18441330 IF: 4,935, anteiliger IF: 1,64484

298. Arnold D, Siewczynski R, Kubicka S, Hacker U, Schmoll HJ: (2008) Kolorektales Karzinom - Primärtherapie bei fortgeschrittener Metastasierung. Onkologie, 31: 3-8 IF: 1,545, anteiliger IF: 0,51495

299. Cassidy J, Schmoll HJ, Van Cutsem E: (2008) Re: Should capecitabine replace infusional flourouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J CLIN ONCOL, 26: 2228 IF: 17,157, anteiliger IF: 5,72014

300. Dietrich A, Mueller T, Paschke R, Kalinowski B, Behlendorf T, Reipsch F, Fruehauf A, Schmoll HJ, Kloft C, Voigt W: (2008) 2-(4-(Tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum(II): a novel platinum compound that overcomes cisplatin resistance and induces apoptosis by mechanisms different from that of cisplatin. J MED CHEM, 51: 5413-22 18698754 IF: 4,898, anteiliger IF: 0,20412

301. Fizazi K, Oldenburg J, Dunant A, Chen I, Salvioni R, Hartmann JT, De Santis M, Daugaard G, Flechon A, de Giorgi U, Tjulandin S, Schmoll HJ, Bouzy J, Fossa SD, Fromont G: (2008) Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. ANN ONCOL, 19: 259-264 IF: 4,935, anteiliger IF: 0,12656

302. Haller DG, Cassidy J, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM, Rothenberg ML, Saltz LB, Schmoll HJ, Allegra C, Bertino JR, Douillard

JY, Gustavsson BG, Milano G, O'Connell M, Rustum Y, Tabernero J, Gilberg F, Sirzen F, Twelves C: (2008) Potential regional differences for the tolerability profiles of fluoropyrimidines. J CLIN ONCOL, 26: 2118-2123 IF: 17,157, anteiliger IF: 0,31779

303. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Stahl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fossa SD, Gardia Del Muro X, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Leiva Galvis O, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Paz Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H: (2008) European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part I. Eur Urol, 53: 478-496 IF: 6,512, anteiliger IF: 0,0268

304. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Stahl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fossa SD, Gardia Del Muro X, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Leiva Galvis O, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Paz Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H: (2008) European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II. Eur Urol, 53: 497-513 IF: 6,512, anteiliger IF: 0,0268

305. Müller CI, Schulmann K, Reinacher-Schick A, Andre N, Arnold D, Tannapfel A, Arkenau H, Hahn SA, Schmoll HJ, Porschen R, Schmiegel W, Graeven U: (2008) Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy . A report of the AIO Colorectal Study Group. INT J COLORECTAL DIS, 23: 1033-39 IF: 1,767, anteiliger IF: 0,05891

306. Schmiegel W, Reinacher-Schick A, Arnold D, Graeven U, Heinemann V, Porschen R, Riemann J, Rödel C, Sauer R, Wieder M, Schmitt W, Schmoll HJ, Seufferlein T, Kopp I, Pox C: (2008) [Update S3-guideline "colorectal cancer" 2008]. Z Gastroenterol, 46: 799-840 18759205 IF: 0,88, anteiliger IF: 0,02257

307. Valentini V, Beets-Tan R, Borras JM, Krivokapic Z, Leer JW, Pahlman L, Rödel C, Schmoll HJ, Scott N, Velde CV, Verfaillie C: (2008) Evidence and research in rectal cancer. Radiother Oncol, 87: 449-474 IF: 3,99, anteiliger IF: 0,14781

308. Van Cutsem E, Dicato M, Haustermans K, Arber N, Bosset JF, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Goldberg R, Glynne-Jones R, Haller D, Kang YK, Kerr D, Labianca R, Minsky BD, Moore M, Nordlinger B, Rougier P, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, Tempero M, Van de Velde C, Zalcberg J: (2008) The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. ANN ONCOL, 19: vi1-vi8 IF: 4,935, anteiliger IF: 0,06856

309. Voigt W, Jordan K, Schmoll HJ: (2008) Advances in the prognosis and treatment of medullary or anaplastic thyroid cancer. EUR J ENDOCRINOL, 4: 66-69 IF: 3,791, anteiliger IF: 1,26354


310. Arnold D, Voigt W, Kiewe P, Behrmann C, Lindemann S, Reif S, Wiesinger H, Giurescu M, Thiel E, Schmoll HJ: (2009) Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial. BRIT J CANCER, 101: 1241-7 19773753 IF: 4,346, anteiliger IF: 1,44852

311. Dansranjavin T, Krehl S, Müller T, Müller LP, Schmoll HJ, Dammann RH: (2009) The role of promoter CpG methylation in the epigenetic control of stem cell related genes during differentiation. CELL CYCLE, 15: 916-924 IF: 4,087, anteiliger IF: 0,34065

312. Jahn P, Renz P, Stukenkemper J, Book K, Kuss O, Jordan K, Horn I, Thoke-Colberg A, Schmoll HJ, Landenberger M: (2009) Reduction of chemotherapy-induced anorexia, nausea, and emesis through a structured nursing intervention: a cluster-randomized multicenter trial. Support Care Cancer, 17: 1543-52 19629539 IF: 2,089, anteiliger IF: 0,08706

313. Jordan K, Kinitz I, Voigt W, Behlendorf T, Wolf HH, Schmoll HJ: (2009) Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist

aprepitant in highly and moderately emetogenic multiple-day chemotherapy. EUR J CANCER, 45: 1184-7 19135359 IF: 4,121, anteiliger IF: 1,37353

314. Jordan K, Behlendorf T, Müller F, Schmoll HJ: (2009) Anthracycline extravasation injuries: management with dexrazoxane. THER CLIN RISK MANAG, 5: 361-6 19536310 IF: 1,3 anteiliger IF: 0,43333

315. Jordan K, Müller F, Schmoll HJ: (2009) New antiemetic strategies - not only in oncology. Internist (Berl), 50: 887-894 IF: 0,34, anteiliger IF: 0,11332

316. Keysser G, Müller L, Schendel M, Schmoll HJ: (2009) [Therapeutic application of mesenchymal stromal cells in autoimmune disease: rationale and initial clinical experience]. Z RHEUMATOL, 68: 220, 222-7 19384552 IF: 0,401, anteiliger IF: 0,13365

317. Mueller T, Luetzkendorf J, Nerger K, Schmoll HJ, Mueller LP: (2009) Analysis of OCT4 expression in an extended panel of human tumor cell lines from multiple entities and in human mesenchymal stem cells. CELL MOL LIFE SCI, 66: 495-503 19023518 IF: 6,09, anteiliger IF: 0,6768

318. Robertson JD, Botwood NA, Rothenberg ML, Schmoll HJ: (2009) Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. CLIN COLORECTAL CANC, 8: 59-60 IF: 1,764, anteiliger IF: 0,58794

319. Schmoll HJ, Arnold D: (2009) When Wishful Thinking Leads to a Misty-Eyed Appraisal: The Story of the Adjuvant Colon Cancer Trials With Edrecolomab. J CLIN ONCOL, 27: 1-4 IF: 17,793, anteiliger IF: 8,8965

320. Schmoll HJ, Jordan K: (2009) Current treatment of high risk testis cancer. EUR J CANCER, 45 Suppl 1: 433-5 19775661 IF: 4,121, anteiliger IF: 2,0605

321. Schmoll HJ, Jordan K, Huddart R, Laguna MP, Horwich A, Fizazi K, Kataja V, ESMO Guidelines Working Group: (2009) Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. ANN ONCOL, 20 Suppl 4: 89-96 19454475 IF: 5,647, anteiliger IF: 1,88215

322. Schmoll HJ, Jordan K, Huddart R, Laguna MP, Horwich A, Fizazi K, Kataja V, ESMO Guidelines Working Group: (2009) Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. ANN ONCOL, 20 Suppl 4: 83-8 19454474 IF: 5,647, anteiliger IF: 1,88215

323. Schmoll HJ, Schmiegel W: (2009) Gastrointestinal tumors. Foreward. Onkologie, 32: 1


324. Seliger G, Mueller LP, Kegel T, Kantelhardt EJ, Grothey A, Groe R, Strauss HG, Koelbl H, Thomssen C, Schmoll HJ: (2009) Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer. INT J GYNECOL CANCER, 19: 1446-53 20009905 IF: 2,179, anteiliger IF: 0,72626

325. Trarbach T, Schmoll HJ: (2009) Rectal cancer and synchronous metastases: resection of primary tumor or not? GASTROEN CLIN BIOL, 33: 1098-1100 IF: 0,928, anteiliger IF: 0,464

326. Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM, Haustermans K, Maingon P, Overgaard J, Pahlman L, Quirke P, Schmoll HJ, Sebag-Montefiore D, Taylor I, van Cutsem E, van de Velde C, Cellini N, Latini P, Scientific C: (2009) Multidisciplinary rectal cancer management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol, 92: 148-163 IF: 4,343, anteiliger IF: 0,08517

327. Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Gruenberger T, Haller D, Haustermans K, Hoff P, Kerr D, Labianca R, Moore M, Nordlinger B, Ohtsu A, Rougier P, Scheithauer W, Schmoll HJ, Sobrero A, Tabernero J, van de Velde C: (2009) The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona 2008. ANN ONCOL, 20: vii1-vii6 IF: 5,647, anteiliger IF: 0,08558


328. Arnold D, Schmoll HJ, Lang H, Knoefel WT, Ridwelski K, Trarbach T, Staib L, Kirchner T, Geissler M, Seufferlein T, Amthauer H, Riess H, Schlitt HJ, Piso P: (2010) Spezielle Therapiesituationen beim metastasierten kolorektalen Karzinom. Onkologie, 33: 8-18 IF: 1,156, anteiliger IF: 0,03212

329. Bukur J, Loeffler D, Massa C, Mueller L, Riemann D, Schmoll HJ, Seliger B: (2010) "Tumor immunology meets oncology IV", 23rd and 24th May 2008 Martin Luther University Halle-Wittenberg, Halle, Germany. CANCER IMMUNOL IMMUN, 59: 955-62 18751976 IF: 4,293, anteiliger IF: 0,28626

330. Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, Marreaud S, Collette L, Lluch JR, Bokemeyer C, Schmoll HJ: (2010) A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in

males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). ANN ONCOL, 22: 1054-1061 IF: 6,452, anteiliger IF: 2,15045

331. Jordan K, Grothey A, Pelz T, Lautenschläger C, Franke U, Schöber C, Schmoll HJ: (2010) Impact of quality of life parameters and coping strategies on postchemotherapy nausea and vomiting. EUR J CANCER CARE, 19: 603-9 19725867 IF: 1,138, anteiliger IF: 0,3793

332. Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J, Kegel T, Schmoll HJ: (2010) The NK-1 receptor-antagonist aprepitant in high-dose (HD) chemotherapy (HD melphalan and HD T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. BONE MARROW TRANSPL, 13: 1-6 IF: 3,66, anteiliger IF: 1,21988

333. Jordan K, Wolf HH, Voigt W, Kegel T, Mueller LP, Behlendorf T, Sippel C, Arnold D, Schmoll HJ: (2010) Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study. BONE MARROW TRANSPL, 45: 1704-9 20228848 IF: 3,66, anteiliger IF: 1,21988

334. Lützkendorf J, Müller LP, Müller T, Caysa H, Nerger K, Schmoll HJ: (2010) Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence. J CELL MOL MED, 14: 2292-304 19508388 IF: 4,608, anteiliger IF: 1,53585

335. Matuszczyk A, Petersen S, Voigt W, Kegel T, Dralle H, Schmoll HJ, Bockisch A, Mann K: (2010) Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium. HORM METAB RES, 42: 61-4 19735058 IF: 2,414, anteiliger IF: 0,13414

336. Mueller T, Mueller LP, Holzhausen HJ, Witthuhn R, Albers P, Schmoll HJ: (2010) Histological evidence for the existence of germ cell tumor cells showing embryonal carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity. HISTOCHEM CELL BIOL, 134: 197-204 20532795 IF: 4,727, anteiliger IF: 1,57551

337. Peinert S, Grothe W, Stein A, Müller LP, Rüssel J, Voigt W, Schmoll HJ, Arnold D: (2010) Safety and efficacy of weekly 5-fluorouracil/ folinic acid/ oxaliplatin/ irinotecan in the first-line treatment of gastrointestinal cancer. Ther Adv Med Oncol, 2: 161-174 IF: 2,8 anteiliger IF: 0,15555

338. Reinacher-Schick A, Arnold D, Trarbach T, Ridwelski K, Bruch HP, Kirchner T, Kubicka S, Schmoll HJ: (2010) Adjuvante Therapie des Kolonkarzinoms. Onkologie, 33: 2-7 IF: 1,156, anteiliger IF: 0,38529

339. Schmiegel W, Pox C, Reinacher-Schick A, Adler G, Arnold D, Fleig W, Fölsch UR, Frühmorgen P, Graeven U, Heinemann V, Hohenberger W, Holstege A, Junginger T, Kopp I, Kühlbacher T, Porschen R, Propping P, Riemann JF, Rödel C, Sauer R, Sauerbruch T, Schmitt W, Schmoll HJ, Seufferlein T, Zeitz M, Selbmann HK: (2010) S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol, 48: 65-136 20072998 IF: 1,131, anteiliger IF: 0,01571

340. Schmoll HJ, Jordan K, Huddart R, Pes MPL, Horwich A, Fizazi K, Kataja V, ESMO Guidelines Working Group: (2010) Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANN ONCOL, 21 Suppl 5: v140-6 20555065 IF: 6,452, anteiliger IF: 2,15045

341. Schmoll HJ, Jordan K, Huddart R, Pes MPL, Horwich A, Fizazi K, Kataja V, ESMO Guidelines Working Group: (2010) Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANN ONCOL, 21 Suppl 5: v147-54 20555066 IF: 6,452, anteiliger IF: 2,15045

342. Van Cutsem E, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F, De Gramont A, Diaz-Rubio E, Ducreux M, Geva R, Glimelius B, Jones RG, Grothey A, Gruenberger T, Haller D, Haustermans K, Labianca R, Lenz HJ, Minsky B, Nordlinger B, Ohtsu A, Pavlidis N, Rougier P, Schmiegel W, van de Velde C, Schmoll HJ, Sobrero A, Tabernero J: (2010) Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona 2009. ANN ONCOL, 21: v1-10 IF: 6,452, anteiliger IF: 0,08273

343. Voigt W, Lorenz K, Schmoll HJ: (2010) Therapie des Schilddrüsenkarzinoms. TUMORDIAGN THER, 1: 18-22 IF: 0,15 anteiliger IF: 0,05

344. Zwierzina H, Bardelli A, Ciardiello F, Gariboldi M, Hakansson L, Lambrechts D, Lind GE, Loeffler-Ragg J, Schmoll HJ, Siena S, Tabernero J, van Cutsem E: (2010) Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials. CURR OPIN MOL THER, 12: 703-11 21154162 IF: 4,023, anteiliger IF: 0,13413

345. Schmoll HJ: (2010) S-1 for advanced colorectal cancer: do we need another oral fluorouracil prodrug? LANCET ONCOL, 11: 808-809 IF: 17,764, anteiliger IF: 1,7764

2010 Summe Bewertung = 15.22854 Summe IF = 75,538

346. Abouassaly R, Fossa SD, Giwercman A, Kollmannsberger C, Motzer RJ, Schmoll HJ, Sternberg CN: (2011) Sequelae of treatment in long-term survivors of testis cancer. Eur Urol, 60: 516-26 21684072 IF: 8,493, anteiliger IF: 0,56631

347. Arnold D, Fietkau R, Hegewisch-Becker S, Höhler T, Knoefel WT, Kubicka S, Lang H, Liersch T, Luster M, Oettle H, Reinacher-Schick A, Ridwelski K, Riess H, Rödel C, Rüschoff J, Schmiegel W, Schmoll HJ, Vanhoefer U: (2011) Gastrointestinale Tumore - interdisziplinäre Diskussion neuer Daten. Onkologie, 34: 1-31 IF: 0,868, anteiliger IF: 0,01809

348. Arnold D, Fietkau R, Hegewisch-Becker S, Höhler T, Knoefel WT, Kubicka S, Lang H, Liersch T, Luster M, Oettle H, Reinacher-Schick A, Ridwelski K, Riess H, Rödel C, Rüschoff J, Schmiegel W, Schmoll HJ, Vanhoefer U: (2011) [Gastrointestinal tumors--interdisciplinary discussion over new data]. Onkologie, 34 Suppl 3: 1-31 21577036 IF: 0,868, anteiliger IF: 0,01809

349. Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, Marreaud S, Collette L, Lluch JRG, Bokemeyer C, Schmoll HJ: (2011) A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). ANN ONCOL, 22: 1054-61 21059637 IF: 6,425, anteiliger IF: 2,14145

350. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll HJ: (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J CLIN ONCOL, 29: 1465-71 21383294 IF: 18,372, anteiliger IF: 6,12339

351. Jordan K, Jahn F, Jahn P, Behlendorf T, Stein A, Ruessel J, Kegel T, Schmoll HJ: (2011) The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. BONE MARROW TRANSPL, 46: 784-9 20838387 IF: 3,746, anteiliger IF: 1,24854

352. Keyszer G, Christopeit M, Fick S, Schendel M, Taute BM, Behre G, Müller LP, Schmoll HJ: (2011) Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases. ARTHRITIS RHEUM-US, 63: 2540-2 21547891 IF: 7,866, anteiliger IF: 2,62174

353. Rüssel J, Stein A, Behrmann C, Hauptmann S, Krummenerl P, Schmoll HJ, Arnold D: (2011) Inflammatory lesions of the peritoneum mimic carcinomatosis after treatment with intravenous chemotherapy and intraperitoneal catumaxomab. J CLIN ONCOL, 29: e644-6 21606410


354. Schmoll HJ, Heissner K: (2011) Current treatment of stage I testicular seminoma. Onkologie, 34: 495-6 21985846 IF: 0,868, anteiliger IF: 0,434

355. Schmoll HJ, Osanto S, Kawai K, Einhorn L, Fizazi K: (2011) Advanced seminoma and nonseminoma: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. UROLOGY, 78: S456-68 21986225 IF: 2,428, anteiliger IF: 0,80925

356. Stein A, Hiemer S, Schmoll HJ: (2011) Adjuvant therapy for early colon cancer: current status. DRUGS, 71: 2257-75 22085384 IF: 4,226, anteiliger IF: 1,40853

357. Surov A, Fiedler E, Holzhausen HJ, Ruschke K, Schmoll HJ, Spielmann RP: (2011) Metastases to the breast from non-mammary malignancies: primary tumors, prevalence, clinical signs, and radiological features. ACAD RADIOL, 18: 565-74 21393030 IF: 1,692, anteiliger IF: 0,14103

358. Tempero MA, Berlin J, Ducreux M, Haller D, Harper P, Khayat D, Schmoll HJ, Sobrero A, Van Cutsem E: (2011) Pancreatic cancer treatment and research: an international expert panel discussion. ANN ONCOL, 22: 1500-6 21199884 IF: 6,425, anteiliger IF: 0,30601

359. Van Cutsem E, Dicato M, Geva R, Arber N, Bang Y, Benson A, Cervantes A, Diaz-Rubio E, Ducreux M, Glynne-Jones R, Grothey A, Haller D, Haustermans K, Kerr D, Nordlinger B, Marshall J, Minsky BD, Kang YK, Labianca R, Lordick F, Ohtsu A, Pavlidis N, Roth A, Rougier P, Schmoll HJ, Sobrero A, Tabernero J, Van de Velde C, Zalcberg J: (2011) The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. ANN ONCOL, 22 Suppl 5: v1-9 21633049 IF: 6,425, anteiliger IF: 0,07934

360. van Cutsem E, Dicato M, Geva R, Arber N, Bang Y, Benson A, Cervantes A, Diaz-Rubio E, Ducreux M, Glynn-Jones R, Grothey A, Haller D, Haustermans K, Kerr D, Nordlinger B, Marshall J, Minsky BD, Kang YK, Labianca R, Lordick F, Ohtsu A, Pavlidis N, Roth A, Rougier P, Schmoll HJ, Sobrero A, Tabernero J, Van de Velde C, Zalcberg J: (2011) The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona 2010. ANN ONCOL, 22: v1-9 IF: 6,425, anteiliger IF: 0,07934

361. Moehler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D, Aust D, Baier P, Baretton G, Bernhardt J, Boeing H, Böhle E, Bokemeyer C, Bornschein J, Budach W, Burmester E, Caca K, Diemer WA, Dietrich CF, Ebert M, Eickhoff A, Ell C, Fahlke J, Feussner H, Fietkau R, Fischbach W,

Fleig W, Flentje M, Gabbert HE, Galle PR, Geissler M, Gockel I, Graeven U, Grenacher L, Gross S, Hartmann JT, Heike M, Heinemann V, Herbst B, Herrmann T, Höcht S, Hofheinz RD, Höfler H, Höhler T, Hölscher AH, Horneber M, Hübner J, Izbicki JR, Jakobs R, Jenssen C, Kanzler S, Keller M, Kiesslich R, Klautke G, Körber J, Krause BJ, Kuhn C, Kullmann F, Lang H, Link H, Lordick F, Ludwig K, Lutz M, Mahlberg R, Malfertheiner P, Merkel S, Messmann H, Meyer HJ, Mönig S, Piso P, Pistorius S, Porschen R, Rabenstein T, Reichardt P, Ridwelski K, Röcken C, Roetzer I, Rohr P, Schepp W, Schlag PM, Schmid RM, Schmidberger H, Schmiegel WH, Schmoll HJ, Schuch G, Schuhmacher C, Schütte K, Schwenk W, Selgrad M, Sendler A, Seraphin J, Seufferlein T, Stahl M, Stein H, Stoll C, Stuschke M, Tannapfel A, Tholen R, Thuss-Patience P, Treml K, Vanhoefer U, Vieth M, Vogelsang H, Wagner D, Wedding U, Weimann A, Wilke H, Wittekind C, AWMF, AWMF: (2011) [German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol, 49: 461-531 21476183 IF: 0,896, anteiliger IF: 0,00028

362. Schmoll HJ: (2011) Do we need oncology trials tailored for the elderly or frail? Lancet, 377: 1725-7 21601694 IF: 38,278, anteiliger IF: 3,8278

363. Schmoll HJ, Hallek M: (2011) Perspectives for onkologie. Onkologie, 34: 659 22156443 IF: 0,868, anteiliger IF: 0,0434

364. Nagtegaal ID1, Quirke P, Schmoll HJ. Has the new TNM classification for colorectal cancer improved care? Nat Rev Clin Oncol. 2011 Oct 18;9(2):119-23.

IF:11,963 anteiliger IF: 3,9877


365. Calabrò F, Albers P, Bokemeyer C, Martin C, Einhorn LH, Horwich A, Krege S, Schmoll HJ, Sternberg CN, Daugaard G: (2012) The contemporary role of chemotherapy for advanced testis cancer: a systematic review of the literature. Eur Urol, 61: 1212-21 22464311 IF: 10,476, anteiliger IF: 0,43659

366. de Gramont A, Van Cutsem E, Schmoll HJ, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F, Im SA, Bodoky G, Salazar R, Maindrault-Goebel F, Shacham-Shmueli E, Bajetta E, Makrutzki M, Shang A, André T, Hoff PM: (2012) Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. LANCET ONCOL, 13: 1225-

33 23168362 IF: 25,117, anteiliger IF: 0,46522

367. Nagtegaal ID, Quirke P, Schmoll HJ: (2012) Has the new TNM classification for colorectal cancer improved care? NAT REV CLIN ONCOL, 9: 119-23 22009076 IF: 15,031, anteiliger IF: 5,00983

368. Saini KS, Taylor C, Ramirez AJ, Palmieri C, Gunnarsson U, Schmoll HJ, Dolci SM, Ghenne C, Metzger-Filho O, Skrzypski M, Paesmans M, Ameye L, Piccart-Gebhart MJ, de Azambuja E: (2012) Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. ANN ONCOL, 23: 853-9 21821551 IF: 7,384, anteiliger IF: 0,20515

369. Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson J, Van Cutsem E: (2012) Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J CLIN ONCOL, 30: 3588-95 22965961 IF: 18,038, anteiliger IF: 6,01207

370. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A: (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. ANN ONCOL, 23: 2479-516 23012255 IF: 7,384, anteiliger IF: 2,46109

371. Stein A, Glockzin G, Wienke A, Arnold D, Edelmann T, Hildebrandt B, Hollerbach S, Illerhaus G, Königsrainer A, Richter M, Schlitt HJ, Schmoll HJ: (2012) Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC Cancer, 12: 356 22897915 IF: 3,333, anteiliger IF: 1,11089

372. Stein A, Hiemer S, Jordan K, Arnold D, Schmoll HJ: (2012) Administration of chemotherapy by an arteriovenous fistula in a patient with metastatic rectal cancer after life-threatening, port thrombosis-associated cava superior syndrome. An option for patients without possibility of peripheral or central venous access. Onkologie, 35: 440-2 22846976 IF: 1, anteiliger IF: 0,3333

373. Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A, Pfreundschuh M, Loeffler M, Glass B; German High-Grade Lymphoma Study Group (DSHNHL). Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012 Dec;13(12):1250-9. IF:0 IF: 0, IF: 25,117 anteiliger IF: 0,52327

374. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardière C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Müller HH, Skogseid B; FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012 Jun 7;366(23):2189-97. IF: 51,658 anteiliger IF: 0,47831


375. Aapro MS, Schmoll HJ, Jahn F, Carides AD, Webb RT: (2013) Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types. Cancer Treat Rev, 39: 113-7 23062719 IF: 6,466, anteiliger IF: 0,71859

376. Bernig T, Jahn F, Witkowsky S, Huehn R, Hentschel A, Kegel T, Schmoll HJ, Körholz D: (2013) Treatment of adolescents and young adults (AYA) with cancer in a multidisciplinary setting: on the way to a highly specialized AYA unit. Klin Padiatr, 225: 335-8 24166088 IF: 1,9 anteiliger IF: 0,10555

377. Christopeit M, Janssen N, Weber T, Bacher U, Lautenschläger C, Oehme A, Kekulé AS, Schmoll HJ: (2013) Cyclosporine area under the curve after allogeneic hematopoietic stem cell transplantation is an indicator of Epstein-Barr virus DNAemia. Leuk Lymphoma, 54: 133-7 22721496 IF: 2,605, anteiliger IF: 0,86825

378. Christopeit M, Lindner A, Surov A, Weber T, Vehreschild MJGT, Bialek R, Schmoll HJ: (2013) Right flank pain and high fever in a neutropenic patient with acute lymphoblastic leukaemia. Mycoses, 56: 90-2 22889321 IF: 1,805, anteiliger IF: 0,60161

379. Dralle H, Musholt TJ, Schabram J, Steinmüller T, Frilling A, Simon D, Goretzki PE, Niederle B, Scheuba C, Clerici T, Hermann M, Kußmann J,

Lorenz K, Nies C, Schabram P, Trupka A, Zielke A, Karges W, Luster M, Schmid KW, Vordermark D, Schmoll HJ, Mühlenberg R, Schober O, Rimmele H, Machens A, German Societies of General and Visceral Surgery Endocrinology Nuclear Medicine Pathology Radiooncology Oncological Hematology and the German Thyroid Cancer Patient Support Organization Ohne Schilddrüse leben e.V: (2013) German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. LANGENBECK ARCH SURG, 398: 347-75 23456424 IF: 2,16, anteiliger IF: 0,02881

380. Jürgensmeier JM, Schmoll HJ, Robertson JD, Brooks L, Taboada M, Morgan SR, Wilson D, Hoff PM: (2013) Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. BRIT J CANCER, 108: 1316-23 23449351 IF: 4,817, anteiliger IF: 0,26766

381. Oldenburg J, Fosså SD, Nuver J, Heidenreich A, Schmoll HJ, Bokemeyer C, Horwich A, Beyer J, Kataja V, ESMO Guidelines Working Group: (2013) Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ANN ONCOL, 24 Suppl 6: vi125-32 24078656 IF: 6,578, anteiliger IF: 0,2743

382. Pox C, Aretz S, Bischoff SC, Graeven U, Hass M, Heußner P, Hohenberger W, Holstege A, Hübner J, Kolligs F, Kreis M, Lux P, Ockenga J, Porschen R, Post S, Rahner N, Reinacher-Schick A, Riemann JF, Sauer R, Sieg A, Scheppach W, Schmitt W, Schmoll HJ, Schulmann K, Tannapfel A, Schmiegel W, Leitlinienprogramm Onkologie der AWMF, Deutschen Krebsgesellschaft e.?V, Deutschen Krebshilfe e.?V: (2013) [S3-guideline colorectal cancer version 1.0]. Z Gastroenterol, 51: 753-854 23955142 IF: 1,671, anteiliger IF: 0,02055

383. Schmiegel W, Reinacher-Schick A, Arnold D, Kubicka S, Freier W, Dietrich G, Geißler M, Hegewisch-Becker S, Tannapfel A, Pohl M, Hinke A, Schmoll HJ, Graeven U: (2013) Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. ANN ONCOL, 24: 1580-7 23463625 IF: 6,578, anteiliger IF: 0,19937

384. Stein A, Schmoll HJ: (2013) Systemic treatment of liver metastases from colorectal cancer. Ther Adv Med Oncol, 5: 193-203 23634197 IF: 2,14 anteiliger IF: 1,07

385. Van Cutsem E, Borràs JM, Castells A, Ciardiello F, Ducreux M, Haq A, Schmoll HJ, Tabernero J: (2013) Improving outcomes in colorectal cancer: where do we go from here? EUR J CANCER, 49: 2476-85 23642327 IF: 4,819, anteiliger IF: 0,26778

386. van de Velde CJH, Aristei C, Boelens PG, Beets-Tan RGH, Blomqvist L, Borras JM, van den Broek CBM, Brown G, Coebergh JW, Cutsem EV, Espin E, Gore-Booth J, Glimelius B, Haustermans K, Henning G, Iversen LH,

Han van Krieken J, Marijnen CAM, Mroczkowski P, Nagtegaal I, Naredi P, Ortiz H, Påhlman L, Quirke P, Rödel C, Roth A, Rutten HJT, Schmoll HJ, Smith J, Tanis PJ, Taylor C, Wibe A, Gambacorta MA, Meldolesi E, Wiggers T, Cervantes A, Valentini V, European Registration of Cancer Care: (2013) EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe. EUR J CANCER, 49: 2784-90 23769991 IF: 4,819, anteiliger IF: 0,0459

387. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):303-12. I IF: 39,207 anteiliger IF:0,68784


388. Bach AG, Schmoll HJ, Beckel C, Behrmann C, Spielmann RP, Wienke A, Abbas J, Surov A: (2014) Pulmonary embolism in oncologic patients: frequency and embolus burden of symptomatic and unsuspected events. ACTA RADIOL, 55: 45-53 23864061 IF: 1,603, anteiliger IF: 0,08913

389. Breugom AJ, Boelens PG, van den Broek CBM, Cervantes A, Van Cutsem E, Schmoll HJ, Valentini V, van de Velde CJH: (2014) Quality assurance in the treatment of colorectal cancer: the EURECCA initiative. ANN ONCOL, 25: 1485-92 24671742 IF: 7,04, anteiliger IF: 0,39142

390. Chu E, Haller D, Cartwright T, Twelves C, Cassidy J, Sun W, Saif MW, McKenna E, Lee S, Schmoll HJ: (2014) Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial. BRIT J CANCER, 110: 1438-45 24548866 IF: 4,836, anteiliger IF: 1,61184

391. Lestuzzi C, Vaccher E, Talamini R, Lleshi A, Meneguzzo N, Viel E, Scalone S, Tartuferi L, Buonadonna A, Ejiofor L, Schmoll HJ: (2014) Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk. ANN ONCOL, 25: 1059-64 24558023 IF: 7,04, anteiliger IF: 2,34643

392. Schmoll HJ, Stein A: (2014) Colorectal cancer in 2013: Towards improved drugs, combinations and patient selection. NAT REV CLIN ONCOL, 11: 79-80 24445520


393. Schmoll HJ, Twelves C, Sun W, O'Connell MJ, Cartwright T, McKenna E, Saif M, Lee S, Yothers G, Haller D: (2014) Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. LANCET ONCOL, 15: 1481-92 25456367 IF: 24,69, anteiliger IF: 8,22918

394. Schmoll HJ, Wittig B, Arnold D, Riera-Knorrenschild J, Nitsche D, Kroening H, Mayer F, Andel J, Ziebermayr R, Scheithauer W: (2014) Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J CANCER RES CLIN, 140: 1615-24 24816725 IF: 3,081, anteiliger IF: 1,0269

395. Stein A, Arnold D, Thuss-Patience PC, Moehler M, Grothe W, Seufferlein T, Reinacher-Schick A, Geissler M, Hofheinz RD, Schmoll HJ: (2014) Docetaxel, oxaliplatin and capecitabine (TEX regimen) in patients with metastatic gastric or gastro-esophageal cancer: results of a multicenter phase I/II study. ACTA ONCOL, 53: 392-8 24024696 IF: 2,997, anteiliger IF: 0,9989

396. van de Velde CJH, Boelens PG, Borras JM, Coebergh JW, Cervantes A, Blomqvist L, Beets-Tan RGH, van den Broek CBM, Brown G, Van Cutsem E, Espin E, Haustermans K, Glimelius B, Iversen LH, van Krieken JH, Marijnen CAM, Henning G, Gore-Booth J, Meldolesi E, Mroczkowski P, Nagtegaal I, Naredi P, Ortiz H, Påhlman L, Quirke P, Rödel C, Roth A, Rutten H, Schmoll HJ, Smith JJ, Tanis PJ, Taylor C, Wibe A, Wiggers T, Gambacorta MA, Aristei C, Valentini V: (2014) EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. EUR J CANCER, 50: 1.e1-1.e34 24183379 IF: 5,417, anteiliger IF: 0,05417

397. Wass M, Behlendorf T, Schädlich B, Mottok A, Rosenwald A, Schmoll HJ, Jordan K: (2014) Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response. EUR J HAEMATOL, 92: 268-70 24330038 IF: 2,066, anteiliger IF: 0,1378

398. Quinten C1, Martinelli F, Coens C, Sprangers MA, Ringash J, Gotay C, Bjordal K, Greimel E, Reeve BB, Maringwa J, Ediebah DE, Zikos E, King MT, Osoba D, Taphoorn MJ, Flechtner H, Schmucker-Von Koch J, Weis J, Bottomley A; Patient Reported Outcomes and Behavioral Evidence (PROBE) and the European Organization for Research and Treatment of Cancer (EORTC) Clinical Groups. A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. Cancer. 2014 Jan 15;120(2):302-11.

IF: 4,889, anteilige IF:0,09054


399. Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D: (2015) Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. ONCOLOGIST, 20: 450-8 25795636 IF: 4,865, anteiliger IF: 0,40525

400. Bauer A, Vordermark D, Seufferlein T, Schmoll HJ, Dralle H, Mau W, Unverzagt S, Boese S, Fach EM, Landenberger M: (2015) Trans-sectoral care in patients with colorectal cancer: Protocol of the randomized controlled multi-center trial Supportive Cancer Care Networkers (SCAN). BMC Cancer, 15: 997 26694748 IF: 3,362, anteiliger IF: 0,1402

401. Grünwald V, Keilholz U, Boehm A, Guntinas-Lichius O, Hennemann B, Schmoll HJ, Ivanyi P, Abbas M, Lehmann U, Koch A, Karch A, Zörner A, Gauler TC: (2015) TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO). ANN ONCOL, 26: 561-7 25527417 IF: 7,04, anteiliger IF: 0,21331

402. Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll HJ, Tveit KM, Gibson F: (2015) A review of the evolution of systemic chemotherapy in the management of colorectal cancer. CLIN COLORECTAL CANC, 14: 1-10 25579803 IF: 2,813, anteiliger IF: 0,1564

403. Haller DG, O'Connell MJ, Cartwright TH, Twelves CJ, McKenna EF, Sun W, Saif MW, Lee S, Yothers G, Schmoll HJ: (2015) Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. ANN ONCOL, 26: 715-24 25595934 IF: 7,04, anteiliger IF: 2,34643

404. Hegewisch-Becker S, Graeven U, Lerchenmüller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, Lange T, Dietrich G, Stoehlmacher J, Tannapfel A, Reinacher-Schick A, Quidde J, Trarbach T, Hinke A, Schmoll HJ, Arnold D: (2015) Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. LANCET ONCOL, 16: 1355-69 26361971 IF: 24,69, anteiliger IF: 0,54812

405. Jahn F, Jordan K, Behlendorf T, Globig C, Schmoll HJ, Müller-Tidow C, Jordan B: (2015) Safety and Efficacy of Liposomal Cytarabine in the

Treatment of Neoplastic Meningitis. ONCOLOGY-BASEL, 89: 137-42 25791073 IF: 2,422, anteiliger IF: 0,16155

406. Ruff P, Ferry DR, Lakom? R, Prausová J, Van Hazel GA, Hoff PM, Cunningham D, Arnold D, Schmoll HJ, Moiseyenko VM, McKendrick JJ, Ten Tije AJ, Vishwanath RL, Bhargava P, Chevalier S, Macarulla T, Van Cutsem E: (2015) Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. EUR J CANCER, 51: 18-26 25466509 IF: 5,417, anteiliger IF: 0,12026

407. Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Hoersch S, Rittweger K, Haller DG: (2015) Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. J CLIN ONCOL, 33: 3733-40 26324362 IF: 18,428, anteiliger IF: 6,14205

408. Sclafani F, Kim TY, Cunningham D, Kim TW, Tabernero J, Schmoll HJ, Roh JK, Kim SY, Park YS, Guren TK, Hawkes E, Clarke SJ, Ferry D, Frödin JE, Ayers M, Nebozhyn M, Peckitt C, Loboda A, Mauro DJ, Watkins DJ: (2015) A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer. JNCI-J NATL CANCER I, 107: djv258 26405092 IF: 12,583, anteiliger IF: 0,23279

409. Shi Q, de Gramont A, Grothey A, Zalcberg J, Chibaudel B, Schmoll HJ, Seymour MT, Adams R, Saltz L, Goldberg RM, Punt CJA, Douillard JY, Hoff PM, Hecht JR, Hurwitz H, Díaz-Rubio E, Porschen R, Tebbutt NC, Fuchs C, Souglakos J, Falcone A, Tournigand C, Kabbinavar FF, Heinemann V, Van Cutsem E, Bokemeyer C, Buyse M, Sargent DJ: (2015) Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. J CLIN ONCOL, 33: 22-8 25385741 IF: 18,428, anteiliger IF: 0,23588

410. Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R, Prausová J, Moiseyenko VM, van Hazel G, Cunningham D, Arnold D, Schmoll HJ, Ten Tije AJ, McKendrick J, Kröning H, Humblet Y, Grávalos C, Le-Guennec S, Andria M, Dochy E, Vishwanath RL, Macarulla T, Tabernero J: (2015) Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. TARGET ONCOL, x: x 26706237 IF: 4, anteiliger IF: 0,0636

411. Wittig B, Schmidt M, Scheithauer W, Schmoll HJ: (2015) MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to

bedside. CRIT REV ONCOL HEMAT, 94: 31-44 25577571 IF: 4,027, anteiliger IF: 1,3422

412.

413. Renfro LA, Grothey A, Kerr D, Haller DG, André T, Van Cutsem E, Saltz L, Labianca R, Loprinzi CL, Alberts SR, Schmoll H, Twelves C, Yothers G, Sargent DJ; Adjuvant Colon Cancer Endpoints (ACCENT) Group; Adjuvant Colon Cancer Endpoints ACCENT Group. Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†.. Ann Oncol. 2015 May;26(5):950-8. IF: 7,04 anteiliger IF: 0,196

414. van den Berg H, Paulussen M, Le Teuff G, Judson I, Gelderblom H,

Dirksen U, Brennan B, Whelan J, Ladenstein RL, Marec-Berard P, Kruseova J, Hjorth L, Kühne T, Brichard B, Wheatley K, Craft A, Juergens H, Gaspar N, Le Deley MC; Euro-EWING99 Group. Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial. Eur J Cancer. 2015 Nov;51(16):2453-64 IF:5,417 anteiliger IF 0,10031

415. Huddart RA1, Gabe R2, Cafferty FH2, Pollock P2, White JD3, Shamash J4, Cullen MH5, Stenning SP2; TE23 Trial Management Group and Collaborators; National Cancer Research Institute Testis Cancer Clinical Studies Group. A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604). Eur Urol. 2015 Mar;67(3):534-43.

IF: 13,938, anteiliger IF 0,66371


416. Renfro LA, Loupakis F, Adams RA, Seymour MT, Heinemann V, Schmoll HJ, Douillard JY, Hurwitz H, Fuchs CS, Diaz-Rubio E, Porschen R, Tournigand C, Chibaudel B, Falcone A, Tebbutt NC, Punt CJA, Hecht JR, Bokemeyer C, Van Cutsem E, Goldberg RM, Saltz LB, de Gramont A, Sargent DJ, Lenz HJ: (2016) Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. J CLIN ONCOL, 34: 144-50 26503203


417. Schmidt H, Boese S, Bauer A, Landenberger M, Lau A, Stoll O, Schmoll HJ, Mauz-Koerholz C, Kuss O, Jahn P: (2016) Interdisciplinary care programme to improve self-management for cancer patients undergoing stem cell transplantation: a prospective non-randomised intervention study. EUR J CANCER CARE, x: x 26857103 IF: 1,564, anteiliger IF: 0,06522

418. Shah MA, Renfro LA, Allegra CJ, André T, de Gramont A, Schmoll HJ, Haller DG, Alberts SR, Yothers G, Sargent DJ: (2016) Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. J CLIN ONCOL, 34: 843-53 26811529 IF: 18,428, anteiliger IF: 0,76845

419. Widder M, Lützkendorf J, Caysa H, Unverzagt S, Wickenhauser C, Benndorf RA, Schmoll HJ, Müller-Tidow C, Müller T, Müller LP: (2016) Multipotent mesenchymal stromal cells promote tumor growth in distinct colorectal cancer cells by a ?1-integrin-dependent mechanism. Int J Cancer, 138: 964-75 26356035 IF: 5,085, anteiliger IF: 0,21204

420. Schmoll HJ :(2016) Targeting HER2: precision oncology for colorectal cancer. LANCET Oncol 2016 (released on 20.04.2016) IF: 24,6, anteiliger IF: 24,6


Cumulative IF total: 1807,55

Date post:	21-Jan-2019
Category:	Documents
Upload:	trannhi
View:	226 times
Download:	0 times

Prof. Dr. med. Hans-Joachim Schmoll · Bibliography according to PubMed with Impact Factor...

Documents